“–‰È‚Å—Í‚ð“ü‚ê‚¢‚Ä‚¢‚éŽæ‚è‘g‚ÝEŒ¤‹†‚Ì‚²Ð‰î

Ž·•M’†

ã‚Ö–ß‚é

‹ÆÑi˜_•¶EŠw‰ï”­•\EŽóÜj

| 2020”N
(ŽóÜj

E”Ç–Ú@–¾i‘“à—¯Šw¶jFTravel Award of JSIBD for the 14th Congress of European Crohnfs and Colitis Organization (ECCO). Natural history and clinical outcomes of patients with ulcerative colitis who are intolerant to 5-aminosalycylic acid agents: a multi-centre cohort studyC“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïC2020

ã‚Ö–ß‚é

| 2019”N
iŒ´’˜˜_•¶j

EKinoshita Hi‘“à—¯Šw¶j, Nishioka H, Ikeda A, Ikoma K, Sameshima Y, Ohi H, Tatsuno M, Kouyama J, Kawamoto C, Mitsui T, Tamura Y, Hashimoto Y, Nishio M, Ogashiwa T, Saigusa Y, Maeda S, Kimura H, Kunisaki R, Koike K: Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Behcet's disease. J Gastroenterol Hepatol, 34(11):1929-1939, 2019.

EYaguchi Ki‰ŠúŒ¤Cˆãj, Sasaki T, Ogashiwa T, Nishio M, Hashimoto Y, Ikeda A, Izumi M, Hanzawa A, Shibata N, Yonezawa H, Sakamaki K, Tateishi Y, Numata K, Maeda S, Kimura H, Kunisaki R: Correlation between the macroscopic severity of Crohn's disease in resected intestine and bowel wall thickness evaluated by water-immersion ultrasonography. Scand J Gastroenterol, 54(11):1331-1338, 2019.

EMadarame Ai‘“à—¯Šw¶j, Kimura H, Kunisaki R: Successful Treatment With Ustekinumab for Enterocutaneous Fistulas in Crohn's Disease. J Crohns Colitis, pii: jjz161. doi: 10.1093/ecco-jcc/jjz161, 2019.

EUchino M, Ikeuchi H, Hata K, Okada S, Ishihara S, Morimoto K, Sahara R, Watanabe K, Fukushima K, Takahashi K, Kimura H, Hirata K, Mizushima T, Araki T, Kusunoki M, Nezu R, Nakao S, Itabashi M, Hirata A, Ozawa H, Ishida T, Okabayashi K, Yamamoto T, Noake T, Arakaki J, Watadani Y, Ohge H, Futatsuki R, Koganei K, Sugita A, Higashi D, Futami K: Changes in the rate of and trends in colectomy for ulcerative colitis during the era of biologics and calcineurin inhibitors based on a Japanese nationwide cohort study. Surg Today, 49(12):1066-1073, 2019.

ESugita A, Koganei K, Tatsumi K, Futatsuki R, Kuroki H, Yamada K, Kimura H, Fukushima T: Postoperative functional outcomes and complications of partially intraanal canal anastomosis in stapled ileal pouch anal anastomosis for ulcerative colitis. Int J Colorectal Dis, 34(7):1317-1323, 2019.

EHata K, Anzai H, Ikeuchi H, Futami K, Fukushima K, Sugita A, Uchino M, Higashi D, Itabashi M, Watanabe K, Koganei K, Araki T, Kimura H, Mizushima T, Ueda T, Ishihara S, Suzuki Y; Research Group for Intractable Inflammatory Bowel Disease of the Ministry of Health, Labour and Welfare of Japan (RGIBD): Surveillance Colonoscopy for Ulcerative Colitis-Associated Colorectal Cancer Offers Better Overall Survival in Real-World Surgically Resected Cases. Am J Gastroenterol, 114(3):483-489, 2019.

ETajiri H, Arai K, Kagimoto S, Kunisaki R, Hida N, Sato N, Yamada H, Nagano M, Susuta Y, Ozaki K, Kondo K, Hibi T: Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. BMC Pediatr, 19(1):351, 2019.

EYanagi T, Ushijima K, Koga H, Tomomasa T, Tajiri H, Kunisaki R, Isihige T, Yamada H, Arai K, Yoden A, Aomatsu T, Nagata S, Uchida K, Ohtsuka Y, Shimizu T: Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan. Intest Res, 17(4):476-485, 2019.

EKumagai H, Kudo T, Uchida K, Kunisaki R, Sugita A, Ohtsuka Y, Arai K, Kubota M, Tajiri H, Suzuki Y, Shimizu T: Adult gastroenterologists' views on transitional care: Results from a survey. Pediatr Int, 61(8):817-822, 2019.

EHisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group: Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]. J Crohns Colitis, 13(9):1097-1104, 2019.

EHisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Matsumoto T; DIAMOND2 Study Group: Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). J Gastroenterol, 54(10):860-870, 2019.

‚Ù‚©

(Šw‰ï”­•\j

EIkeda Ai‘åŠw‰@¶j, Ogashiwa T, Nakamori Y, Mitsui T, Chida K, Hashimoto Y, Tamura Y, Maeda S, Kimura H, Kunisaki R: Efficacy of exclusive enteral nutrition for induction and partial enteral nutrition for maintenance of remission in newly diagnosed paediatric and adolescent Crohnfs disease. The 14th Congress of European Crohnfs and Colitis Organization (ECCO) 2019, Copenhagen, 2019, 3.

ENakamori Yiƒ[ƒe[ƒgˆãŽtj, Ikeda A, Madarame A, Hirayama A, Chida K, Aoki S, Seki K, Saigusa Y, Maeda S, Kimura H, Kunisaki R: Pregnancy outcomes in Japanese women with inflammatory bowel disease treated with thiopurine. The 7th Annual Meeting of Asian Organization for Crohnfs & Colitis (AOCC) 2019, Taipei, 2019, 5.

EMadarame Ai‘“à—¯Šw¶j, Ikeda A, Kinoshita H, Ikoma K, Sameshima Y, Ohi H, Nishioka H, Kouyama J, Kawamoto C, Tatsuno M, Nakamori Y, Hirayama A, Saigusa Y, Kimura H, Kunisaki R: Impact of 5-aminosalicylic Acid on maintenance and natural history of intestinal Behcetfs Disease. The 7th Annual Meeting of Asian Organization for Crohnfs & Colitis (AOCC) 2019, Taipei, 2019, 5.

EHirayama Ai‘“à—¯Šw¶j, Ikeda A, Kinoshita H, Ikoma K, Sameshima Y, Ohi H, Nishioka H, Kouyama J, Kawamoto C, Tatsuno M, Nakamori Y, Madarame A, Saigusa Y, Kimura H, Kunisaki R: Remission Induction and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Mild to Moderate Intestinal Behcetfs Disease. The 7th Annual Meeting of Asian Organization for Crohnfs & Colitis (AOCC) 2019, Taipei, 2019, 5.yExcellent PosterÜz

EHirayama Ai‘“à—¯Šw¶j, Nakamori Y, Madarame A, Ikeda A, Chida K, Fujii A, Shimoyama Y, Kimura H, Kunisaki R: Upper gastrointestinal lesions in Behcetfs disease. The 7th Annual Meeting of Asian Organization for Crohnfs & Colitis (AOCC) 2019, Taipei, 2019, 5.

EKimura H, Kunisaki R, Tatsumi K, Koganei K, Sugita A, Endo I: One stage restorative proctocolectomy with a stapled ileal pouch-anal anastomosis using Hand-Assisted Laparoscopic Surgery (HALS) and Laparoscope-Assested Open Surgery (LAOS) procedure for ulcerative colitis. The American Society of Colon and Rectal Surgeons Annual Scientific Meeting, Cleveland, 2019, 5.

EKunisaki R, Tatsuno M, Kouyama J, Kawamoto C, Nishioka H, Mizoguchi A, Nakamori Y, Mitsui T, Chida K, Hashimoto Y, Tamura Y, Ikeda A, Ogashiwa T, Suzuki R, Maeda S, Kimura H: Therapeutic efficacy and economic impact of half sulfasalazine therapy for refractory ulcerative colitis. The 14th Congress of European Crohnfs and Colitis Organization (ECCO) 2019, Copenhagen, 2019, 3.

ENambu R, Murakoshi T, Kunisaki R, Shimizu H, Mizuochi T, Saito T, Kumagai H, Kato S, Inoue M, Hirano Y, Shimizu T, Tajiri H, Arai K: Disease Course of Pediatric Ulcerative Colitis during Follow-up; a Prospective Registry Study of Japanese Pediatric IBD Patients. The 5th International Symposium on Paediatric Inflammatory Bowel Disease 2019, Hungary, 2019, 9.

E’r“c@—çi‘åŠw‰@¶jC’†X‹`“TCç“cŒ\ŒáC‹´–{@—IC¬”@„C“¡ˆäÊŽqC²X–Ø’q•FC‰ºŽR‹`”ŽC–Ø‘º‰p–¾C‘è—æŽqC–Ø@–ÎCŠÖ@˜a’jF“–‰@‚É‚¨‚¯‚éIBD‡•¹”DP‚ɑ΂·‚éƒ`ƒIƒvƒŠƒ“»Ü“Š—^‚̈À‘S«‚ÌŒŸ“¢iƒRƒAƒVƒ“ƒ|ƒWƒEƒ€jD‘æ15‰ñ“ú–{Á‰»ŠÇŠw‰ïC²‰êC2019, 2.

E’†X‹`“Tiƒ[ƒe[ƒgˆãŽtjCŽOˆä’qOC’JŒûŸéC‹´–{@—I,’r“c@—çC¬”@„Cç“cŒ\ŒåC–Ø‘º‰p–¾C‘è—æŽq,ç—t²˜aŽqC‘å’J•ûŽqCŠâ‰º‰‰‹vCàVZ’mŽ}C“c•Ó”üŽ÷ŽqCˆîŽR‰Ã–¾FƒNƒ[ƒ“•a‚Æf’f‚³‚ê‚Ä‚¢‚½‚ªŠmf‚𓾂ĉü‘P‚µ‚½¬’°‰Š‚̈ê—áD_“Þ쬒°‰æ‘œŒ¤‹†‰ï, ‰¡•lC2019, 2.

EVˆäŸ‘åC‘º‰zFŽŸC‘è—æŽqC“ì•”—²—ºC‰Á“¡‘òŽqCâV“¡@•C…—ŽŒš‹PCˆä㊲‘åCŒF’JG‹KC–”‹g@ŒcCΖÑ@’C–]ŒŽ‹M”ŽC“cK@mC“ú‰q“ˆ‰h‘¾˜YC¼—F’ÎCH“¡FLC¼–’”É—YC´…‘׊xC•½–ì—F—œC´…r–¾Ff’fŒã3”NŠÔ‚Å‚ÌŽ¡—Â̎À‘Ô@“ú–{¬Ž™‰ŠÇ«’°Ž¾Š³ƒŒƒWƒXƒgƒŠŒ¤‹†2019D‘æ19‰ñ“ú–{¬Ž™IBDŒ¤‹†‰ïC‘åãC2019, 2.

EΖÑ@’C‘º‰zFŽŸC‘è—æŽqC”‹Œ´^ˆê˜YC´…‘׊xCâV“¡@•C’†ŽR‰ÀŽqC–ö@’‰GCˆä㊲‘åCŒF’JG‹KCŠâŠÔ@’BC–]ŒŽ‹M”ŽC“cK@mC•½–ì—F—œCVˆäŸ‘åF¬Ž™Šú”­ÇƒNƒ[ƒ“•a‚É‚¨‚¯‚é‰h—{—Ö@‚É‚æ‚éˆÛŽ—Ö@‚Ì—L—p«EˆÛŽŒø‰Ê‚ÌŒŸ“¢@“ú–{¬Ž™‰ŠÇ«’°Ž¾Š³ƒŒƒWƒXƒgƒŠŒ¤‹†2019D‘æ19‰ñ“ú–{¬Ž™IBDŒ¤‹†‰ïC‘åãC2019, 2.

E–Ø‘º‰p–¾C“c‘º—TŽqCŽOˆä’qLC‹´–{@—IC’r“c@—çC¬”@„C‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“c@ºC‰““¡@ŠiF‰ŠÇ«’°Ž¾Š³‚ɑ΂·‚éŠO‰ÈŽ¡—Â̬тƕûŒü«@¶•¨Šw“I»ÜŽž‘ã‚É‚¨‚¯‚éƒNƒ[ƒ“•a’°ŠÇ•a•ÏŽèp‚Ì’·Šú—\ŒãiƒVƒ“ƒ|ƒWƒEƒ€jD‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïC‘åãC2019, 4.

E“c‘º—TŽqiƒ[ƒe[ƒgˆãŽtj, –Ø‘º ‰p–¾, ‘è —æŽq, ‘å“c v—R, š è ŽåÅ, “¿‹v Œ³•F, Žsì –õŽj, Ε” “ÖŽm, ‰““¡ŠiF’×ᇫ‘å’°‰Š‚ɇ•¹‚µ‚½‘å’°Žîᇂ̌»ó‚Æ‘ÎôD‘æ119‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïC‘åãC2019, 4.

E‰Á“¡ŽÀ‹èi‰ŠúŒ¤CˆãjC’r“c@—çC’†X‹`“TC‹´–{ —IC¬”@„C²X–Ø’q•FC“¡ˆäÊŽqC–Ø‘º‰p–¾C‘è—æŽqC–Ø@–ÎFRTNFR‘̂ƃXƒeƒƒCƒh“Š—^’†‚É”DP‚µA•êŽq‚ɃŠƒXƒeƒŠƒAŠ´õǂ𕹔­‚µ‚½‚ª‹~–½‚Å‚«‚½’×ᇫ‘å’°‰Š‚̈ê—áD‘æ115‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïuˆãŠw¶EŒ¤Cˆã‚Ì“à‰ÈŠw‚±‚Æ‚Í‚¶‚ß2019vC–¼ŒÃ‰®C2019, 4.

E‚ŽRƒ‰ÀiˆãŠw•”Šw¶jC’r“c@—çC’†X‹`“TC‹´–{@—IC¬”@„C“¡ˆäÊŽqC–Ø‘º‰p–¾C‘è—æŽqF’×ᇫ‘å’°‰Š‚ɑ΂·‚éRTNFR‘Ì“Š—^’†‚É‚ˆÀ“®–¬‰Š‚ð”­Ç‚µ‚½3—á‚ÌŒŸ“¢D‘æ115‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïuˆãŠw¶EŒ¤Cˆã‚Ì“à‰ÈŠw‚±‚Æ‚Í‚¶‚ß2019vC–¼ŒÃ‰®C2019, 4.

E‘è—æŽqC‹v•ÄØC‹´–{@—IC’†X‹`“TC”Ç–Ú@–¾C’r“c@—çC•½ŽR“Ö‘åC–Ø‘º‰p–¾CŽOŽ}—S•ãCÀ“c˜aŽiF’×ᇫ‘å’°‰Š‚ɑ΂·‚éŒo• “I’´‰¹”g‚ÌV‹KŠˆ“®«ƒXƒRƒAFUCUS score‚Ìì¬iƒRƒAƒVƒ“ƒ|ƒWƒEƒ€jD“ú–{’´‰¹”gˆãŠw‰ï‘æ92‰ñŠwpW‰ïC“Œ‹žC2019, 5.

EŽÄ“c®”üi—Õ°ŒŸ¸‹ZŽtjC•Ÿ–ì‚悵‚ÝC˜aò”ü‹½C•½ˆäDC ’†X‹`“TC’r“c@—çC –Ø‘º‰p–¾C‘è—æŽqFÁ‰»ŠÇ’´‰¹”gŠŒ©‚©‚çŠmf‚ÉŽŠ‚Á‚½C’n’†ŠC”M—Þ‰’°‰ŠiMEFVˆâ“`ŽqŠÖ˜A’°‰Šj‚̈ê—áiƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“jD“ú–{’´‰¹”gˆãŠw‰ï‘æ92‰ñŠwpW‰ïC“Œ‹žC2019, 5.

E¼”ö‹§Žji‘åŠw‰@¶jC‘è—æŽqCŽÅ“c@ÂC•½àV‹ÓŒáC–¡‰ª—mˆêCç—t²˜aŽqCˆîŽRŠì–¾C‘åì´FC–Ø‘º‰p–¾C‘O“c@œÄF’×ᇫ‘å’°‰Š‚̉ŠÇ”͈͓à‚ɇ•¹‚µ‚½‹˜Ž•ó•a•Ï‚Ì“Á’¥D‘æ99‰ñ“ú–{“àŽ‹‹¾ŠwŠE‘‰ïC‹ž“sC2019, 6.

E¬—Ñ—º‰îC•½àV‹ÓŒáCàV“c“ÖŽjC’r“c—Ç•ãC¼”ö‹§ŽjC•Ÿ’n„‰pC²“¡’mŽqC‘è—æŽqC‘O“c@œÄF’×ᇫ‘å’°‰Š‚É‚¨‚¯‚éESD‚̑Ó–«D‘æ99‰ñ“ú–{“àŽ‹‹¾ŠwŠE‘‰ïC‹ž“sC2019, 6.

E–Ø‘º‰p–¾Cç“cŒ\ŒåC‹´–{@—IC’r“c@—çC¬”@„C‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“c@ºC‰““¡@ŠiFIBD‚ɑ΂·‚鎊“KŽèpŽžŠú‚ÆpŽ®‘I‘ð@Crohn•a‚Ì•«‡–@‚É‹‚ß‚ç‚ê‚é‚à‚͉̂½‚©?iƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“jD‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ïC˜a‰ÌŽRC2019, 7.

E¬‹àˆäˆê—²C’C–¤Œ’ŽuC“ñ–Ø@—¹C•–Ø”Ž‰îC–Ø‘º‰p–¾C™“c@ºFA˜JAAŠwŠú‚Ì’×ᇫ‘å’°‰Š“—á‚ɑ΂·‚éŠO‰ÈŽ¡—ÃŽŠ“K‘I‘ðŽžŠú‚ÆpŽ®D‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ïC˜a‰ÌŽRC2019, 7.

E™“c@ºC¬‹àˆäˆê—²C’C–¤Œ’ŽuC“ñ–Ø@—¹C•–Ø”Ž‰îCrˆäŸ•FC–Ø‘º‰p–¾C•Ÿ“‡P’jF’×ᇫ‘å’°‰Š‚ɑ΂·‚鬊J• ‚É‚æ‚éˆêŠú“IJŒ^‰ñ’°”Xãè–åŠÇ•«‡p‚ÌŽèpŽè‹ZD‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ïC˜a‰ÌŽRC2019, 7.

E’C–¤Œ’ŽuC™“c@ºC¬‹àˆäˆê—²C“ñ–Ø@—¹C•–Ø”Ž‰îC–Ø‘º‰p–¾CrˆäŸ•FC•Ÿ“‡P’jF¬Ž™’×ᇫ‘å’°‰ŠŽèp—á‚ÌpŒã’·ŠúŒo‰ß‚ÌŒŸ“¢D‘æ75‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ïC˜a‰ÌŽRC2019, 7.

E’r“c@—çi‘åŠw‰@¶jC’†X‹`“TC’¹’JŒšˆê˜YC”Ç–Ú@–¾C•½ŽR“Ö‘åCú㌴@Š°C“¡ˆäÊŽqC²X–Ø’q•FC‰ºŽR‹`”ŽC–Ø‘º‰p–¾C‘è—æŽqC–Ø@–ÎC ŠÖ@˜a’jF“–‰@‚É‚¨‚¯‚é“ú–{lIBD‡•¹”DP‚ɑ΂·‚éƒ`ƒIƒvƒŠƒ“»Ü“Š—^‚̈À‘S«‚ÌŒŸ“¢D‘æ4‰ñ“ú–{•ê«“à‰ÈŠw‰ï‘‰ïEŠwpW‰ïC“Œ‹žC2019, 7.

E’¹’JŒšˆê˜Yiƒ[ƒe[ƒgˆãŽtjC–Ø‘º‰p–¾C’†X‹`“TC”Ç–Ú@–¾C’r“c@—çC•½ŽR“Ö‘åCú㌴@Š°C‘è—æŽqC“nç³@ƒCΕ”“ÖŽmCŽsì–õŽjCš èŽåÅC‰““¡@ŠiF’×ᇫ‘å’°‰ŠŠÖ˜AŠà‚É‚¨‚¯‚éƒT[ƒxƒCƒ‰ƒ“ƒX“àŽ‹‹¾‚Ì—L—p«D‘æ82‰ñ“ú–{—Õ°ŠO‰ÈŠw‰ï‘‰ïC‘åãC2019, 10.

EΖÑ@’C‘º‰zFŽŸC‘è—æŽqC”‹Œ´^ˆê˜YC´…‘׊xCâV“¡@•C’†ŽR‰ÀŽqC–ö@’‰GCˆä㊲‘åCŒF’JG‹KCŠâŠÔ@’BC–]ŒŽ‹M”ŽC“cK@mC•½–ì—F—œCVˆäŸ‘åF“ú–{¬Ž™‰ŠÇ«’°Ž¾Š³ƒŒƒWƒXƒgƒŠ‚ð—p‚¢‚½¬Ž™Šú”­ÇƒNƒ[ƒ“•a‚ɑ΂·‚é‰h—{—Ö@‚ÌŽg—pŽÀ‘Ԃ̉ðÍD‘æ47‰ñ“ú–{¬Ž™‰h—{Á‰»ŠíŠÌ‘Ÿ•aŠw‰ï‘‰ïC“Œ‹žC2019, 10.

E–Ø‘º‰p–¾Cç“cŒ\ŒåC’¹’JŒšˆê˜YCú㌴@Š°C‰““¡@ŠiFHALS‰SŽÒ‚ɑ΂·‚éHALSŒ‹’°ˆŸ‘S“E“±“ü‚ÌŽÀÛD‘æ10‰ñHALS Group MeetingC“Œ‹žC2019, 10D

E–Ø‘º‰p–¾Cç“cŒ\ŒåC‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“c@ºC‰““¡@ŠiF‰ñ’°”Xãè–åŠÇ•«‡p‚Ì‘å’°”S–ŒŽc‘¶‚ɑ΂·‚éBody mass index‚̉e‹¿D‘æ27‰ñÁ‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC_ŒËC2019, 11.

E’r“c@—çi‘åŠw‰@¶jC’†X‹`“TC”Ç–Ú@–¾C•½ŽR“Ö‘åC“¡ˆäÊŽqC‰ºŽR‹`”ŽC–Ø‘º‰p–¾C‘è—æŽqC‘O“c@œÄC–Ø@–ÎCŠÖ@˜a’jF“–‰@‚É‚¨‚¯‚é“ú–{lIBD‡•¹”D•w‚ɑ΂·‚éƒ`ƒIƒvƒŠƒ“»Ü“Š—^‚̈À‘S«D‘æ27‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC_ŒËC2019.11

E¬‹àˆäˆê—²C’C–¤Œ’ŽuC“ñ–Ø@—¹C•–Ø”Ž‰îC’†”ö‰rˆêC–Ø‘º‰p–¾C™“c@ºF¬’°‘å’°Šà‚ð‡•¹‚µ‚½ƒNƒ[ƒ“•aÇ—á‚Ì—Õ°Šw“I“Á’¥‚ÆŒo‰ßD‘æ27‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC_ŒËC2019, 11.

E’¹’JŒšˆê˜Yiƒ[ƒe[ƒgˆãŽtjC–Ø‘º‰p–¾C’†X‹`“TC”Ç–Ú@–¾C’r“c@—çC•½ŽR“Ö‘åCú㌴@Š°C‘è—æŽqC“nç³@ƒCΕ”“ÖŽmCŽsì–õŽjCš èŽåÅC‰““¡@ŠiF’×ᇫ‘å’°‰ŠŠÖ˜AŠà‚É‚¨‚¯‚éƒT[ƒxƒCƒ‰ƒ“ƒX“àŽ‹‹¾‚Ì—L—p«D‘æ81‰ñ“ú–{—Õ°ŠO‰ÈŠw‰ïC‚’mC2019, 11.

E™“c@ºC¬‹àˆäˆê—²C’C–¤Œ’ŽuC“ñ–Ø@—¹C•–Ø”Ž‰îCrˆäŸ•FC’†”ö‰rˆêC–Ø‘º‰p–¾C•Ÿ“‡P’jFCrohn•a‚ɇ•¹‚µ‚½’¼’°ãè–åŠÇŠà‚Ì—Õ°“I“Á’¥‚ÆŽ¡—ÃŒo‰ß‚©‚ç‚Ý‚½Ž¡—Ö@‚ÌŒŸ“¢D‘æ75‰ñ“ú–{‘å’°ãè–å•aŠw‰ïC‰¡•lC2019, 11.

E’C–¤Œ’ŽuC™“c@ºC¬‹àˆäˆê—²C“ñ–Ø@—¹C•–Ø”Ž‰îC’†”ö‰rˆêC–Ø‘º‰p–¾CrˆäŸ•FC•Ÿ“‡P’jF‰ŠÇ«’°Ž¾Š³ŠÖ˜AŽîᇂɑ΂·‚éf—Ẩۑè‚Æ«—ˆ“W–]@’×ᇫ‘å’°‰Š‡•¹Šà‚ɑ΂·‚鎊“KpŽ®‚ÌŒŸ“¢D‘æ75‰ñ“ú–{‘å’°ãè–å•aŠw‰ïC‰¡•lC2019, 11.

E¬‹àˆäˆê—²C’C–¤Œ’ŽuC“ñ–Ø@—¹C•–Ø”Ž‰îC’†”ö‰rˆêC–Ø‘º‰p–¾C™“c@ºFƒNƒ[ƒ“•a‚ɇ•¹‚·‚éãè–å•a•Ï‚ɑ΂·‚鎡—Ã@ƒNƒ[ƒ“•a‚̓«’¼’°ãè–å•a•Ï‚ɑ΂·‚é’¼’°Ø’fpŽ{s—á‚Ì’·ŠúŒo‰ßD‘æ75‰ñ“ú–{‘å’°ãè–å•aŠw‰ïC‰¡•lC2019, 11.

E”Ç–Ú@–¾i‘“à—¯Šw¶jC—§–ìŽ÷C’†X‹`“TC’r“c@—çC•½ŽR“Ö‘åC’¹’JŒ’ˆê˜YCú㌴@Š°C–Ø‘º‰p–¾C‘è—æŽqC—é–Ø—ºˆêF“’×ᇫ‘å’°‰Š‚ɑ΂·‚é halfƒXƒ‹ƒtƒ@ƒTƒ‰ƒWƒ“—Ö@‚Ì—LŒø«‚¨‚æ‚шã—Ôï팸Œø‰Ê‚ÌŒŸ“¢iƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“jD‘æ10‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ï(JSIBD)ŠwpW‰ïC•Ÿ‰ªC2019, 11.

E•½ŽR“Ö‘åi‘“à—¯Šw¶jC¬”@„Cò@—m•½C‚ŽRƒ‰ÀC’†X‹`“TC’r“c@—çC”Ç–Ú@–¾C’¹’JŒ’ˆê˜YCú㌴@Š°C–Ø‘º‰p–¾C‘è—æŽqF’†“™Ç`dÇ‚ðŽå‘Ì‚Æ‚·‚鬎™ƒNƒ[ƒ“•a‚ɑ΂·‚émodified Exclusive Enteral Nutrition (EEN)—Ö@iƒVƒ“ƒ|ƒWƒEƒ€jD‘æ10‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ï(JSIBD)ŠwpW‰ïC•Ÿ‰ªC2019, 11.

Eú㌴@Š°i‘“à—¯Šw¶jC–Ø‘º‰p–¾C’¹’JŒšˆê˜YC’†X‹`“TC’r“c@—çC”Ç–Ú@–¾C•½ŽR“Ö‘åC‘è—æŽqCŸ–”Œ’ŽŸC“y“c–¾•FC‰““¡@ŠiF’×ᇫ‘å’°‰Š‚ÌÄŒš–@‚É‚¨‚¯‚épŒã”r•Ö‹@”\‚Æ—\Œã‚ÌŒŸ“¢D‘æ10‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ï(JSIBD)ŠwpW‰ïC•Ÿ‰ªC2019, 11.

E’†X‹`“Tiƒ[ƒe[ƒgˆãŽtjC’r“c@—çC”Ç–Ú@–¾C•½ŽR“Ö‘åC“¡ˆäÊŽqC‰ºŽR‹`”ŽCr–ØŒª‘¾˜YC–Ø‘º‰p–¾C‘è—æŽqFƒEƒXƒeƒLƒkƒ}ƒu‚ª–³Œø‚¾‚Á‚½ƒNƒ[ƒ“•aÇ—áD_“ÞìCDŽ¡—ÃŒ¤‹†‰ïC‰¡•lC2019, 11.

E•½ŽR“Ö‘åi‘“à—¯Šw¶jC¼‰ª@“µC’r“c@—çC’†X‹`“TC”Ç–Ú@–¾C¶‹î¡“úŽqCŽL“‡—mˆêC‘åˆäG‹vCŽOŽ}—S•ãC–؉º—TlC–Ø‘º‰p–¾C‘è—æŽqFƒx[ƒ`ƒFƒbƒg•a‚Ì’°•a•Ï‚ɑ΂·‚é5-ƒAƒ~ƒmƒTƒŠƒ`ƒ‹Ž_»Ü‚É‚æ‚銰‰ð“±“üŒø‰Ê‚¨‚æ‚Ñ“àŽ‹‹¾“I‰ü‘P‚ÌŒŸ“¢D‘æ3‰ñ“ú–{ƒx[ƒ`ƒFƒbƒg•aŠw‰ïC‰¡•lC2019, 11.

E•½ŽR“Ö‘åi‘“à—¯Šw¶jC’†X‹`“TC”Ç–Ú@–¾C’r“c@—çC“¡ˆäÊŽqC‰ºŽR‹`”ŽC’¹’JŒšˆê˜YCú㌴@Š°C–Ø‘º‰p–¾C‘è—æŽqFƒx[ƒ`ƒFƒbƒg•aã•”Á‰»ŠÇ•a•Ï‚Ì“Á’¥D‘æ3‰ñ“ú–{ƒx[ƒ`ƒFƒbƒg•aŠw‰ïC‰¡•lC2019, 11.

(ŽóÜj

EHirayama Ai‘“à—¯Šw¶j: Excellent PosterÜDRemission Induction and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Mild to Moderate Intestinal Behcetfs Disease. The 7th Annual Meeting of Asian Organization for Crohnfs & Colitis (AOCC) 2019, Taipei, 2019, 5.

E•½ŽR“Ö‘åi‘“à—¯Šw¶jF Travel Award of JSIBD for the 7th Annual Meeting of Asian Organization for Crohnfs and Colitis (AOCC). Remission Induction and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Mild to Moderate Intestinal Behcetfs DiseaseC“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïC2019.

ã‚Ö–ß‚é

| 2018”N
iŒ´’˜˜_•¶j

ENishio Mi‘åŠw‰@¶j, Ishii Y, Hashimoto Y, Otake H, Ogashiwa T, Tsuda S, Yasuhara H, Saigusa Y, Kimura H, Maeda S, Kunisaki R: Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis. Scand J Gastroenterol, 53(10-11):1236-1244, 2018.

ETsuda Si‘“à—¯Šw¶j, Kunisaki R, Kato J, Murakami M, Nishio M, Ogashiwa T, Yoshida T, Kimura H, Kitano M: Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res, 16(4):579-587, 2018.

EIkeuchi H, Uchino M, Sugita A, Futami K, Fukushima K, Hata K, Koganei K, Kusunoki M, Uchida K, Nezu R, Kimura H, Takahashi K, Itabashi M, Kameyama H, Higashi D, Koyama F, Ueda T, Mizushima T, Suzuki Y: Long-term outcomes following restorative proctocolectomy ileal pouch-anal anastomosis in pediatric ulcerative colitis patients: Multicenter national study in Japan. Ann Gastroenterol Surg, 2(6):428-433, 2018.

EFukushima K, Sugita A, Futami K, Takahashi K, Motoya S, Kimura H, Yoshikawa S, Kinouchi Y, Iijima H, Endo K, Hibi T, Watanabe M, Sasaki I, Suzuki Y, Surgical Research Group, the Research Committee of Inflammatory Bowel Disease, the Ministry of Health, Welfare and Labor of Japan. Postoperative therapy with infliximab for Crohnfs disease: a 2-year prospective randomized multicenter study in Japan. Surg Today, 48(6):584-590, 2018.

EUchino M, Ikeuchi H, Sugita A, Futami K, Watanabe T, Fukushima K, Tatsumi K, Koganei K, Kimura H, Hata K, Takahashi K, Watanabe K, Mizushima T, Funayama Y, Higashi D, Araki T, Kusunoki M, Ueda T, Koyama F, Itabashi M, Nezu R, Suzuki Y; a research grant on intractable disease affiliated with the Japan Ministry of Health Labor Welfare: Pouch functional outcomes after restorative proctocolectomy with ileal-pouch reconstruction in patients with ulcerative colitis: Japanese multi-center nationwide cohort study. J Gastroenterol, 53(5):642-651, 2018.

EHisamatsu T, Kunisaki R, Nakamura S, Tsujikawa T, Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M; CERISIER Trial group: Effect of elemental diet combined with infliximab dose escalation in patients with Crohnfs disease with loss of response to infliximab: CERISIER trial. Aliment Pharmacol Ther, 16(3):494-498, 2018.

EKobayashi T, Hisamatsu T, Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto T, Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa T, Sasaki M, Yokoyama K, Yoshimura N, Watanabe K, Katafuchi M, Watanabe M, Hibi T: Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. Intest Res, 16(2):168-177, 2018

EMatsuoka K, Uemura Y, Kanai T, Kunisaki R, Suzuki Y, Yokoyama K, Yoshimura N, Hibi T: Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. Dig Endosc, 63(7):1910-1919, 2018.

EMatsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T: Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol, 53(3):305-353, 2018.

EWatanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group: Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohnfs Disease. Clin Gastroenterol Hepatol, 16(4):542-549, 2018.

EŽÂè ‘å, ¬—Ñ´“T, ‘è—æŽq, ‹v¼—ˆê, ’·À ½, ‚‹´Œ«ˆê, Šâ’j ‘×, —é–ØN•v, “n•Ó Žç, ”‹´“¹˜N, ’¹‹ –¾: ’×ᇫ‘å’°‰Š‚ɑ΂·‚éƒT[ƒxƒCƒ‰ƒ“ƒX“àŽ‹‹¾FƒKƒCƒhƒ‰ƒCƒ“‚ÆŽÀÛ‚Ì‘Šˆá. “ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŽGŽ, 60(4):1033-1043, 2018.

‚Ù‚©

(Šw‰ï”­•\j

EHashimoto Yi‘“à—¯Šw¶j, Kume N, Sato K, Kanemura T, Haga A, Ishii Y, Nishio M, Otake H, Takahashi N, Ogashiwa T, Izumi M, Hanzawa A, Yonezawa H, Saigusa Y, Maeda S, Kimura H, Kunisaki R: Development of a novel transabdominal ultrasound disease activity score in patients with ulcerative colitis (UCUS score). The 13th Congress of European Crohnfs and Colitis Organization (ECCO) 2018, Vienna, 2018, 2.

ENishio Mi‘åŠw‰@¶j, Shibata W, Kunisaki R, Ajioka Y, Hirasawa K, Ueda W, Okawa K, Otake H, Ogashiwa T, Takase A, Chiba S, Inayama Y, Kimura H, Maeda S: A novel candidate pathway for development of in patients atypical serrated lesions with KRAS mutation in ulcerative colitis. The 13th Congress of European Crohnfs and Colitis Organization (ECCO) 2018, Vienna, 2018, 2.

EHashimoto Yi‘“à—¯Šw¶j, Kume N, Mitsui T, Ikeda A, Tamura Y, Ogashiwa T, Izumi M, Hanzawa A, Yonezawa H, Saigusa Y, Maeda S, Kimura H, Kunisaki R: Development of a novel transabdominal ultrasound disease activity score in patients with ulcerative colitis (UCUS score). The 212th Falk Symposium, Kyoto, 2018.9. iPoster AwardsŽöÜj

EIkeda A,i‘åŠw‰@¶j Nishioka H, Kinoshita H, Mitsui T, Tamura Y, Hashimoto Y, Ogashiwa T, Fujii A, Sasaki T, Ikoma K, Ohi H, Sameshima Y, Kimura H, Kunisaki R: Short- and long-term efficacy of 5-aminosalicylic Acid for Intestinal Behcetfs Disease. The 212th Falk Symposium, Kyoto, 2018.9.

EOtake Hi‘“à—¯Šw¶j, Ishii Y, Kanemura T, Haga A, Mitsui T, Hashimoto Y, Ikeda A, Nishio M, Ogashiwa T, Kimura H, Mashima H, Kunisaki R: Efficacy of mesalazine powder on upper gastrointestinal lesions involved in inflammatory bowel disease. The 212th Falk Symposium, Kyoto, 2018.9.

EYaguchi Ki‰ŠúŒ¤Cˆãj, Sasaki T, Mitsui T, Tamura Y, Hashimoto Y, Ikeda A, Ogashiwa T, Fujii A, Izumi M, Hanzawa A, Shibata N, Yonezawa H, Numata K, Maeda S, Kimura H, Kunisaki R: Correlation between macroscopic severity of Crohn disease in resected intestine and bowel wall thickness as evaluated by water-immersion ultrasonography. The 212th Falk Symposium, Kyoto, 2018.9.

ETanaka H, Motoya S, Shibuya t, Osada T, Ito A, Kobayashi T, Kunisaki R, Hongo H, Tanida S, Kokuma S, Hosoi E: Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in 125 elderly patients with inflammatory bowel disease: A multi-centre cohort study. The 13th Congress of European Crohnfs and Colitis Organization (ECCO) 2018, Vienna, 2018, 2.

EKimura H, Kunisaki R, Tatsumi K, Koganei K, Sugita A, Endo I: High body mass index as a risk factor for a large amount of retained rectal mucosa after stapled ileal pouch-anal anastomosis for ulcerative colitis. The American Society of Colon and Rectal Surgeons Annual Scientific Meeting, Nashville, 2018, 5

ETanaka H, Motoya S, Shibuya t, Osada T, Ito A, Kobayashi T, Kunisaki R, Hongo H, Tanida S, Kokuma S, Hosoi E: Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in 125 elderly patients with inflammatory bowel disease: A multi-centre cohort study. Digestive Disease Week 2018, Washington, 2018, 6.

EKobayashi R, Hirasawa K, Sato C, Nishio M, Ogashiwa T, Kunisaki R, Maeda S: Colorectal endoscopic submucosal dissection for patients with ulcerative colitis. Digestive Disease Week 2018, Washington, 2018, 6.

E‘è—æŽqC‹´–{ —IC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C¬” „C²X–Ø’q•FC‘º“cˆËŽqC‚‹´O‹BC‚‹´’¼sC–Ø‘º‰p–¾C“c’†^—C¬–ì^‘¾˜YC–ö’¬¹ŽC‹àŒ“O˜aF¬Ž™Šú”­ÇƒNƒ[ƒ“•a‚Æf’f‚³‚êC‘¢ŒŒŠ²×–EˆÚA‚ªŽ{s‚³‚ꂽX˜A½ƒŠƒ“ƒp‘BÇŒóŒQ2Œ^iXIAPŒ‡‘¹Ç)Ç—á‚ÌŽ¡—ÃŒo‰ßD‘æ18‰ñ“ú–{¬Ž™IBDŒ¤‹†‰ïC“Œ‹žC2018, 2.

EâV“¡ •Cˆä㊲‘åC‘è—æŽqC“ì•”—²—ºC‘º‰zFŽŸCŠp“c•¶•FCÎ–Ñ ’C“cK mC…—ŽŒš‹PC‰Á“¡ ‘òŽqC‹g”Nr•¶CŠâ“c’¼”üC‹g“c‰p¶C“à“cŒbˆêC´…‘׊xC•½–ì—F—œCVˆäŸ‘åF“ú–{¬Ž™‰ŠÇ«’°Ž¾Š³ƒŒƒWƒXƒgƒŠŒ¤‹†•ñ2018@ŽèpÇ—á‚ÌŒŸ“¢. ‘æ18‰ñ“ú–{¬Ž™IBDŒ¤‹†‰ïC“Œ‹žC2018, 2.

E‹´–{ —Ii‘“à—¯Šw¶jC‹v•ÄØCΈä‹`lC‹à‘º’m‹PC–F‰ê ‹ÅC‚‹´O‹BC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C¬” „‚Pj˜aò”ü‹½C”¼àVH”¿C•ÄàVL”üCŽOŽ}—S•ãC–Ø‘º‰p–¾C‘è—æŽqF’×ᇫ‘å’°‰Š‚ɑ΂·‚éV‹K‘ÌŠOŽ®USŠˆ“®«ƒXƒRƒA‚Ìì¬. ‘æ14‰ñ“ú–{Á‰»ŠÇŠw‰ï‘‰ïŠwpW‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC“Œ‹žC2018, 2.

E‘å’|‚Í‚é‚©i‘“à—¯Šw¶jC‹´–{ —IC¼”ö‹§ŽjC¬” „C‚‹´’¼sC–Ø‘º‰p–¾C‘è—æŽqF7”NŠÔšq“f‰º—Ÿ‚ðŒJ‚è•Ô‚µC‰ñ’°multiple lymphomatous polyposis (MLP)‚ÌŠŒ©‚©‚çŠmf‚ÉŽŠ‚Á‚½ˆê—áD‘æ19‰ñ_“Þ쬒°‰æ‘œŒ¤‹†‰ïC‰¡•lC2018.3.

E–Ø‘º‰p–¾C‚‹´O‹BC‹´–{ —IC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C¬” „C‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“c ºC‰““¡ ŠiFƒNƒ[ƒ“•a’°ŠÇ•a•ÏŽèp‚ÌŒ»‹µ‚Æ“W–]. ‘æ118‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïC“Œ‹žC2018.4.

E‚‹´O‹Biƒ[ƒe[ƒgˆãŽtjC–Ø‘º‰p–¾C‘è—æŽqC‰““¡ ŠiF¬Ž™’×ᇫ‘å’°‰ŠŽèp—á‚ÌŒŸ“¢. ‘æ118‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïC“Œ‹žC2018.4.

E™“c ºC¬‹àˆäˆê—²C’C–¤Œ’ŽuC“ñ–Ø —¹C•–Ø”Ž‰îCrˆäŸ•FC¬Œ´ ®C–Ø‘º‰p–¾C•Ÿ“‡P’jFCrohn•a‰‰ñ’°ŠÇØœŒãÇ—á‚ÌpŒãÄ”­‚É‚æ‚éÄŽèp—á‚Ì•a‘Ô‚ÉŠÖ‚·‚錟“¢. ‘æ118‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïC“Œ‹žC2018.4.

E¬‹àˆäˆê—²C’C–¤Œ’ŽuC“ñ–Ø —¹C•–Ø”Ž‰îC–Ø‘º‰p–¾C™“c ºFIBDŠO‰ÈŽ¡—Â̌»‹µ‚Æ“W–] ’×ᇫ‘å’°‰Š‚ɑ΂·‚éŠO‰ÈŽ¡—Â̌»‹µ. ‘æ118‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïC“Œ‹žC2018.4.

E’C–¤Œ’ŽuC™“c ºC¬‹àˆäˆê—²C“ñ–Ø —¹C•–Ø”Ž‰îC¬Œ´ ®C–Ø‘º‰p–¾CrˆäŸ•FC•Ÿ“‡P’jF‘å’°Šà‡•¹’×ᇫ‘å’°‰ŠŽèp—á‚Ìãè–åŠÇ”S–Œ”²‹Ž•”‚É‚¨‚¯‚éŠàEdysplasia”­¶—¦D‘æ118‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïC“Œ‹žC2018.4.

E‹v•ÄØiˆãŠw•”Šw¶jC‹´–{ —IC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C¬” „C•ÄàVL”üCŽOŽ}—S•ãC–Ø‘º‰p–¾C‘è—æŽqF’×ᇫ‘å’°‰Š‚ɑ΂·‚éV‹K‘ÌŠOŽ®’´‰¹”gŠˆ“®«ƒXƒRƒA(UCUS score)‚Ìì¬.@‘æ115‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïuˆãŠw¶EŒ¤Cˆã‚Ì“à‰ÈŠwƒTƒ~ƒbƒg2018vC‹ž“sC2018, 4.@y—DG‰‰‘èÜC—DGŽw“±ŽÒÜŽóÜz

E¼‰ª “µiˆãŠw•”Šw¶jC‘è—æŽqC‹´–{ —IC‘å’|‚Í‚é‚©C¼”ö‹§ŽjC¬” „C²X–Ø’q•FC‘º“cˆËŽqC–Ø‘º‰p–¾Fƒx[ƒ`ƒFƒbƒg•a‚Ì’°ŠÇ•a•Ï‚ɑ΂·‚é5-ƒAƒ~ƒmƒTƒŠƒ`ƒ‹Ž_»Ü‚É‚æ‚銰‰ð“±“üŒø‰Ê‚ÌŒŸ“¢.@‘æ115‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïuˆãŠw¶EŒ¤Cˆã‚Ì“à‰ÈŠwƒTƒ~ƒbƒg2018vC‹ž“sC2018, 4.

E²“¡‰Á“Þi‘“à—¯Šw¶jC‘è—æŽqCÀ“c˜aŽiC‹´–{ —IC‘å’|‚Í‚é‚©C¼”ö‹§ŽjC¬” „C‹´–{^ˆêCâˆä“c Œ÷C@–Ø‘º‰p–¾FƒNƒ[ƒ“•aØœ’°ŠÇ‚É‚¨‚¯‚é…Z–@’´‰¹”gŒŸ¸‚Ì•Ç‘w\‘¢ŠŒ©‚Æ•a—ŠŒ©‚Ì”äŠr.@‘æ115‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïuˆãŠw¶EŒ¤Cˆã‚Ì“à‰ÈŠwƒTƒ~ƒbƒg2018vC‹ž“sC2018, 4.

E’r“c —çi‘åŠw‰@¶jC¼‰ª “µCŽOˆä’qLC“c‘º—TŽqC‹´–{ —IC¬” „C“¡ˆäÊŽqC²X–Ø’q•FC–Ø‘º‰p–¾C‘è—æŽqFƒx[ƒ`ƒFƒbƒg•a‚Ì’°ŠÇ•a•Ï‚ɑ΂·‚é5-ƒAƒ~ƒmƒTƒŠƒ`ƒ‹Ž_»Ü‚É‚æ‚銰‰ð“±“üŒø‰Ê‚ÌŒŸ“¢D‘æ9‰ñIBD‚ƖƉu‚ðŒê‚é‰ïC‰¡•lC2018, 5.

E’r“c —çi‘åŠw‰@¶jCŽOˆä’qLC‹´–{ —ICç“cŒ\ŒáC¬” „C²X–Ø’q•FC“¡ˆäÊŽqC‰ºŽR‹`”ŽC–Ø‘º‰p–¾C‘è—æŽqFŒûoCã•”Á‰»ŠÇC‰ñ’°‚É•a•Ï‚ð”F‚ß‚é‚—îŽÒƒNƒ[ƒ“•a‹^‚¢Ç—áD‘æ51‰ñ_“ÞìIBDƒ~ƒjƒJƒ“ƒtƒ@C‰¡•lC2018, 5.

EŽOˆä’qLiƒ[ƒe[ƒgˆãŽtjC’r“c —çC‹´–{ —IC¬” „C²X–Ø’q•FC“¡ˆäÊŽqC“c‘º—TŽqC–Ø‘º‰p–¾C‘è—æŽqFŒ´ˆö•s–¾‚̬’°‰Š‚ÉŒûoEH“¹EˆÝ‚É’×ᇂ𕹔­‚µ‚½1—áD‘æ50‰ñ_“ÞìIBDƒ~ƒjƒJƒ“ƒtƒ@C‰¡•lC2018, 5.

E–Ø‘º‰p–¾C‚‹´ ’¼sC‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“c ºC‰““¡ ŠiFBody mass index‚’l‚͉ñ’°”Xãè–åŠÇ•«‡p‚É‚¨‚¯‚éŽc‘¶‘å’°”S–Œ‘‰Á‚̊댯ˆöŽq‚Å‚ ‚éD‘æ73‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï’èŠúŠwpW‰ïCŽ­Ž™“‡C2018, 7.

E™“c ºC¬‹àˆäˆê—²C’C–¤Œ’ŽuC“ñ–Ø —¹C•–Ø”Ž‰îCrˆäŸ•FC¬Œ´ ®C–Ø‘º‰p–¾C•Ÿ“‡P’jF’×ᇫ‘å’°‰Š‚ɑ΂·‚é‰ñ’°”Xãè–åŠÇ•«‡pŒã“àŽ‹‹¾ŒŸ¸‚É‚æ‚é‰ñ’°”XCãè–åŠÇ‚Ì•a—ŠŒ©‚ÆŠàƒT[ƒxƒCƒ‰ƒ“ƒXD‘æ73‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï’èŠúŠwpW‰ïCŽ­Ž™“‡C2018, 7.

E¬‹àˆäˆê—²C’C–¤Œ’ŽuC“ñ–Ø —¹C•–Ø”Ž‰îC–Ø‘º‰p–¾C™“c ºFƒNƒ[ƒ“•a‚̓«’¼’°ãè–å•a•Ï‚ɑ΂·‚é’¼’°Ø’fp‚̃^ƒCƒ~ƒ“ƒOD‘æ73‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï’èŠúŠwpW‰ïCŽ­Ž™“‡C2018, 7.

E’C–¤Œ’ŽuC™“c ºC¬‹àˆäˆê—²C“ñ–Ø —¹C•–Ø”Ž‰îC¬Œ´ ®C–Ø‘º‰p–¾CrˆäŸ•FC•Ÿ“‡P’jF‘å’°Šà‡•¹’×ᇫ‘å’°‰ŠŽèp—á‚É‚¨‚¯‚éãè–åŠÇ‚ÌŠà@dysplasia”­¶—¦‚ƃŠƒXƒNˆöŽqD‘æ73‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï’èŠúŠwpW‰ïCŽ­Ž™“‡C2018, 7.

E“ñ–Ø —¹C¬‹àˆäˆê—²C’C–¤Œ’ŽuC•–Ø”Ž‰îC¬Œ´ ®C–Ø‘º‰p–¾CrˆäŸ•FC™“c ºC•Ÿ“‡P’jF’×ᇫ‘å’°‰ŠpŒã‰ñ’°”X‰Š‡•¹Ç—á‚Ì—Õ°Œo‰ß‚Æ–â‘è“_‘æD73‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ï’èŠúŠwpW‰ïCŽ­Ž™“‡C2018, 7.‘º“cˆËŽqC’r“c —çCŽOˆä’qLC“c‘º—TŽqC‹´–{ —IC¬” „C“¡ˆäÊŽqC²X–Ø’q•FC–Ø‘º‰p–¾C‘è—æŽqFƒNƒ[ƒ“•aÇ—á‚ɑ΂·‚éƒEƒXƒeƒLƒkƒ}ƒu‚̈À‘S«‚Æ—LŒø«DCrohnfs disease Conference in KanagawaC‰¡•lC2018, 8.

E‹´–{ —Ii‘“à—¯Šw¶jC’†X‹`“TCç“cŒ\ŒáC’r“c —çC¬” „C“¡ˆäÊŽqC²X–Ø’q•FC‰ºŽR‹`”ŽC–Ø‘º‰p–¾C‘è—æŽqCÂ–Ø –ÎCŠÖ ˜a’jFƒCƒ“ƒtƒŠƒLƒVƒ}ƒu‚ɃAƒUƒ`ƒIƒvƒŠƒ“•¹—pŒã–³Ž–•ª•Ø‚ÉŽŠ‚Á‚½“ƒNƒ[ƒ“•aÇ—á‚ÌŒŸ“¢D_“ÞìƒNƒ[ƒ“•aŒ¤‹†‰ïC‰¡•lC2018, 10.

E“c’†_‹IC–{’J ‘CàF’J’q‹`C’·“c‘¾˜YCˆÉ“¡ˆŸ—R”üC¬—ÑŽõ‹vC‘è—æŽqC–{‹½mŽuC’J“c—@ŽjC׈ä‰hŽ¡Fè÷—±‹…‹z’…—Ö@(GMA)‚Ì‚—ǫ’°Ž¾Š³Š³ŽÒ125—á‚É‚¨‚¯‚éˆÀ‘S«‚Æ—LŒø«‚ÌŒŸ“¢@‘½Ž{Ý‹¤“¯ƒŒƒgƒƒXƒyƒNƒeƒBƒuƒRƒz[ƒgŒ¤‹†D‘æ39‰ñ“ú–{ƒAƒtƒFƒŒƒVƒXŠw‰ïŠwp‘å‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC‰ªŽRC2018, 10.

E–Ø‘º‰p–¾C“c‘º—TŽqC‘è—æŽqC‘å“cv—RCš èŽåÅC“¿‹vŒ³•FCŽsì–õŽjCΕ”“ÖŽmC‰““¡ŠiDƒVƒ“ƒ|ƒWƒEƒ€u‰ŠÇ«”­Šà‚ÌÅ‘Oüv@‰ŠÇ«’°Ž¾Š³‚É‚¨‚¯‚é”­Šà‚ÌŒ»ó‚Æ–â‘è“_D‘æ23‰ñ“ú–{ŠO‰È•a—Šw‰ïŠwpW‰ïiƒVƒ“ƒ|ƒWƒEƒ€jD‰¡•lC2018, 10D

ENishio Mi‘åŠw‰@¶j, Shibata W, Ajioka Y, Hirasawa K, Maeda S, Kunisaki RFA Novel Pathway for the Formation of Atypical Serrated Intestinal Neoplasm Defined by KRAS Mutation in Ulcerative ColitisD‘æ26‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC_ŒËC2018, 11.@yThe Best Presenter Award in International SessionŽóÜz

E‘º“cˆËŽqC‹´–{ —IC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C¬” „C‚‹´O‹BC‚‹´’¼sC–Ø‘º‰p–¾C‘è—æŽqFƒNƒ[ƒ“•aÇ—á‚ɑ΂·‚éƒEƒXƒeƒLƒkƒ}ƒu‚̈À‘S«‚Æ—LŒø«D‘æ26‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC_ŒËC2018, 11.

E‹´–{ —Ii‘“à—¯Šw¶jC‹v•ÄØC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C¬” „C•ÄàVL”üCŽOŽ}—S•ãC–Ø‘º‰p–¾C‘è—æŽqF’×ᇫ‘å’°‰Š‚ɑ΂·‚éV‹K‘ÌŠOŽ®USŠˆ“®«ƒXƒRƒA(UCUS scone)‚Ìì¬D‘æ26‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC_ŒËC2018, 11.

E‹´–{ —Ii‘“à—¯Šw¶jC‹v•ÄØCŽOˆä’qLC“c‘º—TŽqC’r“c —çC¬” „C“¡ˆäÊŽqC²X–Ø’q•FC‘º“cˆËŽqCŽOŽ}—S•ãC–Ø‘º‰p–¾C‘è—æŽqF’×ᇫ‘å’°‰Š‚ɑ΂·‚éŒo• “I’´‰¹”giGIUSj‚ÌV‹KŠˆ“®«ƒXƒRƒA:UCUS score‚É‚æ‚鎡—ÃŒø‰Êƒ‚ƒjƒ^ƒŠƒ“ƒOD‘æ9‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïiJSIBDjŠwpW‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC‹ž“sC2018, 11.

EŽOˆä’qOiƒ[ƒe[ƒgˆãŽtjC¼”ö‹§ŽjC’r“c —çC‹´–{ —IC¬” „C“¡ˆäÊŽqC²X–Ø’q•FC“c‘º—TŽqC•½àV‹ÓŒáC‘O“c œÄC–Ø‘º‰p–¾C‘è—æŽqC–¡‰ª—mˆêF’×ᇫ‘å’°‰Š‚ɇ•¹‚µ‚½‘å’°‹˜Ž•ó•a•Ï‚Ì—Õ°“I“Á’¥‚Æ—\Œã‚ÌŒŸ“¢D‘æ9‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïiJSIBDjŠwpW‰ïC‹ž“sC2018, 11.@yƒ|ƒXƒ^[—DG‰‰‘èÜŽóÜz

E’r“c —çi‘åŠw‰@¶jC¼‰ª “µCŽOˆä’qOC“c‘º—TŽqC‹´–{ —IC¬” „C“¡ˆäÊŽqC²X–Ø’q•FC¶‹î¡“úŽqCŽL“‡—mˆêC‘åˆäG‹vC‘O“c œÄC–Ø‘º‰p–¾C‘è—æŽqFƒx[ƒ`ƒFƒbƒg•a’°ŠÇ•a•Ï‚ɑ΂·‚éŒoŒû5-ƒAƒ~ƒmƒTƒŠƒ`ƒ‹Ž_»Ü‚Ì—LŒø«D‘æ9‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïiJSIBDjŠwpW‰ïC‹ž“sC2018, 11.

E”¨ Œ[‰îC“n糑–¾C–¡‰ª—mˆêCŒõŽRŒcˆêC“n•ÓŒ›Ž¡C‰Ôˆä—msC’‡£—TŽuC‘è—æŽqC¼“cŒ\“ñCŠâØ—´ˆêC”ó“cMKC“c’†M“ñC’|“à‹`–¾C‘å’˘a˜NC‘ºã ˜a¬C¬—Ñ´“TCŠâ’j ‘×C’·–x³˜aC”Ñ’Ë•¶‰lCŒÜ\—’³LC•½“cˆê˜YCH“¡i‰pC¼–{Žå”VCã–앶ºC“n•Ó ŒºC’rã‰ë”ŽCˆÉ“Œ—zŽqC‘å’ëKŽ¡Cˆäã‰i‰îC—FŽŸ’¼‹PC•—Ñ ‹œC™Œ´Œ’ˆêC—é–ØN•vC“n•Ó ŽçC“ú”ä‹I•¶F’×ᇫ‘å’°‰Š‡•¹‘å’°ŠàƒT[ƒxƒCƒ‰ƒ“ƒX‚É‚¨‚¯‚é‘_Œ‚¶ŒŸ‚ƃ‰ƒ“ƒ_ƒ€¶ŒŸ‚̃‰ƒ“ƒ_ƒ€‰»”äŠrŽŽŒ±D‘æ9‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïiJSIBDjŠwpW‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC‹ž“sC2018, 11.

E–Ø‘º‰p–¾C“c‘º—TŽqCŽOˆä’qLC‹´–{—IC’r“c—çC¬”„C‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“cºC‰““¡ŠiFdÇ’×ᇫ‘å’°‰ŠŽ¡—Âɂ¨‚¯‚é“à‰È‚ÆŠO‰È‚̘AŒgD‘æ73‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïiƒVƒ“ƒ|ƒWƒEƒ€jCVhC2018, 11D

E¼”ö‹§Žji‘åŠw‰@¶jCŽÅ“c ÂC•½àV‹ÓŒáC–¡‰ª—mˆêC‘O“c œÄC‘è—æŽqF’×ᇫ‘å’°‰Š‚̉ŠÇ”͈͂ɇ•¹‚·‚鋘Ž•ó•a•Ï‚Ì“Á’¥D‘æ107‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ïŠÖ“ŒŽx•”—á‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC“Œ‹žC2018, 12.

E‚Ù‚©

(ŽóÜj

E‹v•ÄØiˆãŠw•”Šw¶jD—DG‰‰‘èÜC—DGŽw“±ŽÒÜŽóÜD’×ᇫ‘å’°‰Š‚ɑ΂·‚éV‹K‘ÌŠOŽ®’´‰¹”gŠˆ“®«ƒXƒRƒA(UCUS score)‚Ìì¬.@‘æ115‰ñ“ú–{“à‰ÈŠw‰ï‘‰ïEu‰‰‰ïuˆãŠw¶EŒ¤Cˆã‚Ì“à‰ÈŠwƒTƒ~ƒbƒg2018vC‹ž“sC2018, 4.

ENishio Mi‘åŠw‰@¶jFThe Best Presenter Award in International Session. A Novel Pathway for the Formation of Atypical Serrated Intestinal Neoplasm Defined by KRAS Mutation in Ulcerative ColitisD‘æ26‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC_ŒËC2018, 11.

EHashimoto Yi‘“à—¯Šw¶jFPoster Awards. Development of a novel transabdominal ultrasound disease activity score in patients with ulcerative colitis (UCUS score). The 212th Falk Symposium, Kyoto, 2018.9.

EŽOˆä’qOiƒ[ƒe[ƒgˆãŽtjFƒ|ƒXƒ^[—DG‰‰‘èÜD’×ᇫ‘å’°‰Š‚ɇ•¹‚µ‚½‘å’°‹˜Ž•ó•a•Ï‚Ì—Õ°“I“Á’¥‚Æ—\Œã‚ÌŒŸ“¢D‘æ9‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïiJSIBDjŠwpW‰ïC‹ž“sC2018, 11.

ã‚Ö–ß‚é

| 2017”N
(˜_•¶j

EKimura H, Suwa H, Takahashi T, Watanabe K, Sugae S, Saito S, Kubota T, Koganei K, Sugita A, Fujii S, Ota M, Ichikawa Y, Endo I: Long-Term outcomes after colectomy in patients with Familial Adenomatous Polyposis. Int Surg, 101:400-405, 2016. (Published in 2017)

EShibata W, Sohara M, Wu R, Kobayashi K, Yagi S, Yaguchi K, Iizuka Y, Iwasa M, Nakahata H, Yamaguchi T, Matsumoto H, Okada M, Taniguchi K, Hayashi A, Inazawa S, Inagaki N, Sasaki T, Koh R, Kinoshita H, Nishio M, Ogashiwa T, Ookawara A, Miyajima E, Oba M, Ohge H, Maeda S, Kimura H, Kunisaki R: Incidence and Outcomes of Central Venous Catheter-related Blood Stream Infection in Patients with Inflammatory Bowel Disease in Routine Clinical Practice Setting. Inflamm Bowel Dis, 23(11):2042-2047, 2017.

EInoue E, Hata K, Kimura H, Yamaguchi K, Nojima M, Endo I, Shinozaki M: Altered expression of microRNAs in patients with pouchitis after restorative proctocolectomy. Surg Today, 47(12):1484-1491, 2017.

EUchino M, Ikeuchi H, Sugita A, Futami K, Watanabe T, Fukushima K, Tatsumi K, Koganei K, Kimura H, Hata K, Takahashi K, Watanabe K, Mizushima T, Funayama Y, Higashi D, Araki T, Kusunoki M, Ueda T, Koyama F, Itabashi M, Nezu R, Suzuki Y; a research grant on intractable disease affiliated with the Japan Ministry of Health Labor Welfare: Pouch functional outcomes after restorative proctocolectomy with ileal-pouch reconstruction in patients with ulcerative colitis: Japanese multi-center nationwide cohort study. J Gastroenterol, DOI: 10.1007/s00535-017-1389-z, 2017.

EUchida K, Ohtsuka Y, Yoden A, Tajiri H, Kimura H, Isihige T, Yamada H, Arai K, Tomomasa T, Ushijima K, Aomatsu T, Nagata S, Otake K, Matsushita K, Inoue M, Kudo T, Hosoi K, Takeuchi K, Shimizu T: Immunosuppressive medication is not associated with surgical site infection after surgery for intractable ulcerative colitis in children. Intractable Rare Dis Res, 6(2):106-113, 2017.

ENakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group: Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther, 46(9):873-882, 2017.

EKawakami A, Tanaka M, Naganuma M, Maeda S, Kunisaki R, Yamamoto-Mitani N: What strategies do ulcerative colitis patients employ to facilitate adherence?. Patient Prefer Adherence, 11:157-163, 2017.

EShinozaki M, Kobayashi K, Kunisaki R, Hisamatsu T, Naganuma M, Takahashi KI, Iwao Y, Suzuki Y, Watanabe M, Itabashi M, Torii A, Takazoe M, Sugita A: Surveillance for dysplasia in patients with ulcerative colitis: Discrepancy between guidelines and practice. Dig Endosc, 29(5):584-593, 2017.

ETsuchiya K, Hayashi R, Fukushima K, Hibiya S, Horita N, Negi M, Itoh E, Akashi T, Eishi Y, Motoya S, Takeuchi Y, Kunisaki R, Fukunaga K, Nakamura S, Yoshimura N, Takazoe M, Iizuka B, Suzuki Y, Nagahori M, Watanabe M: Caudal type homeobox 2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis. J Gastroenterol Hepatol, 32(5):1032-1039, 2017.

EOno S, Okano T, Hoshino A, Yanagimachi M, Hamamoto K, Nakazawa Y, Imamura T, Onuma M, Niizuma H, Sasahara Y, Tsujimoto H, Wada T, Kunisaki R, Takagi M, Imai K, Morio T, Kanegane H: Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan.J Clin Immunol, 37(1):85-91, 2017.

EKawakami A, Tanaka M, Ochiai R, Naganuma M, Kunisaki R, Kazuma K: Difficulties in Performing Mesalazine Enemas and Factors Related to Discontinuation Among Patients With Ulcerative Colitis. Gastroenterol Nurs, 40(2):101-108, 2017.

EHosoi K, Ohtsuka Y, Fujii T, Kudo T, Matsunaga N, Tomomasa T, Tajiri H, Kunisaki R, Ishige T, Yamada H, Arai K, Yoden A, Ushijima K, Aomatsu T, Nagata S, Uchida K, Takeuchi K, Shimizu T: Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan. J Gastroenterol Hepatol, 32(1):114-119, 2017.

(Šw‰ï”­•\j

EKunisaki R, Nishio M, Ogashiwa T, Otake H, Inoue E, Kimura H: Double-Dose Infliximab Therapy in Crohn's Disease: appropriate time to evaluate efficacy and predictors of long-term outcome. The 12th Congress of European Crohn's and Colotis Organization (ECCO) 2017, Balcerona, 2017, 2.

EOgashiwa T, Nishio M, Otake H, Inoue E, Kimura H, Kunisaki R: Efficacy of intravenous cyclosporine in fulminant steroid-refractory ulcerative colitis with massive bleeding: A retrospective, observational study. The 12th Congress of European Crohn's and Colotis Organization (ECCO) 2017, Balcerona, 2017, 2.

ENishio M, Shibata W, Ajioka Y, Hirasawa K, Ueda W, Okawa k, Otake H, Ogashiwa T, Takase A, Chiba S, Inayama Y, Kimura H, Kunisaki R, Maeda S: A novel candidate pathway for development of neoplasms with serrated morphology in patients with ulcerative colitis. The 12th Congress of European Crohn's and Colotis Organization (ECCO) 2017, Balcerona, 2017, 2.

EKimura H, Kunisaki R, Tatsumi K, Koganei K, Sugita A, Endo I: The site of recurrence and the management plan for postoperative Crohn's disease in the biologic era. The American Society of Colon and Rectal Surgeons Annual Scientific Meeting, Seattle, 2017, 6.

ENishio M, Shibata W, Ajioka Y, Kunisaki R, Maeda S: A novel candidate pathway for development of neoplasms with serrated morphology in patients with ulcerative colitis. GI research Academy 2017, Tokyo, 2017, 6.

EH Kimura: Case study, Exploring optimal clinical approaches. YOKOHAMA IBD Clinical Forum, Yokohama, 2017, 11.

E–Ø‘º‰p–¾Cˆäã‰p”üC¬” „C‘å’|‚Í‚é‚©C¼”ö‹§ŽjC‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“c ºC‰““¡ ŠiFÄŽèp—á‚©‚ç‚Ý‚½ƒNƒ[ƒ“•aŽèpŒã‚Ì–â‘è“_D‘æ13‰ñ“ú–{Á‰»ŠÇŠw‰ï‘‰ïŠwpW‰ïC–¼ŒÃ‰®C2017, 2.

E¬” „C¼”ö‹§ŽjC‘å’|‚Í‚é‚©C¼—Ñ^‰›C–Ø‘º‰p–¾C‘è—æŽqF¬Ž™ƒNƒ[ƒ“•a‚ɑ΂·‚é‰h—{—Ö@‚É‚æ‚銰‰ð“±“ü‚¨‚æ‚ÑŠ°‰ðˆÛŽŒø‰Ê‚ÌŒŸ“¢iƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“j. ‘æ32‰ñ“ú–{Ö¬Œo’°‰h—{Šw‰ïŠwpW‰ïC‰ªŽRC2017, 2.

E¬” „C¼”ö‹§ŽjC‘å’|‚Í‚é‚©Cˆäã‰p”üC–Ø‘º‰p–¾C‘è—æŽqF–{‰ïi2016/6j’ñŽ¦Ç—áF2—á‚ÌŒo‰ß•ñ. ‘æ47‰ñ_“ÞìIBDƒ~ƒjƒJƒ“ƒtƒ@C‰¡•lC2017, 2.

E–Ø‘º‰p–¾FƒNƒ[ƒ“•a‚ɑ΂·‚éƒqƒ…ƒ~ƒ‰‚Ì‘—Ê@‚Ç‚ñ‚ÈŠ³ŽÒ‚ÉA‚ǂ̃^ƒCƒ~ƒ“ƒO‚ªÅ“K‚©HƒNƒ[ƒ“•a‚Ìãè–å•a•Ï‚Ö‚Ìf—ÃAƒvƒ[ƒ`DBIO‚É‚æ‚鎡—ÃÅ“K‰»‚ðl‚¦‚é‰ïC“Œ‹žC2017, 3.

Eˆäã‰p”üC–Ø‘º‰p–¾C‘å’|‚Í‚é‚©C¼”ö‹§ŽjC¬” „C‘è—æŽqC‰““¡ ŠiF‘å’°‘S“E‰ñ’°”Xãè–å(ŠÇ)•«‡Œã‚ÉL”͂Ȭ’°‰Š‚ð”­Ç‚µ‚½’×ᇫ‘å’°‰Š‚ÌÇ—á‚ÌŒŸ“¢.@‘æ117‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïC‰¡•lC2017, 4.

E‹´–{ —IC’†ÏL‹MC¬” „C‚‹´O‹BC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C²X–Ø’q•FC–Ø‘º‰p–¾C‘è—æŽqCŽR‘O³bFŠÖ߃ŠƒEƒ}ƒ`‚ɑ΂·‚鶕¨Šw“I»Ü“Š—^’†‚É’×ᇫ‘å’°‰Š‚ð”­Ç‚µ‚½1—á.@‘æ8‰ñ‰ŠÇ«’°Ž¾Š³‚ƖƉu‚ðŒê‚é‰ïC‰¡•lC2017, 6.

E‘è—æŽqC‹´–{ —IC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C¬” „C‚‹´O‹BC–Ø‘º‰p–¾FVisual Analog Scale(VAS)‚ð—p‚¢‚½‰ŠÇ«’°Ž¾Š³Š³ŽÒ‚ÌŽ¾Š³AŽ¡—ÃXƒgƒŒƒX‚ÉŠÖ‚·‚é«·‚ÌŒŸ“¢.@‘æ13‰ñÁ‰»Ší•a‚É‚¨‚¯‚é«·ˆãŠwˆã—ÃŒ¤‹†‰ïC‰ªŽRC2017, 7.

E–Ø‘º‰p–¾Cˆäã‰p”üC‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“c ºC‰““¡ ŠiF’×ᇫ‘å’°‰Š‚̉ñ’°”Xãè–åŠÇ•«‡p‚É‚¨‚¯‚éŽc‘¶‘å’°”S–Œ‘‰Á‚̊댯ˆöŽq.@‘æ72‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï’èŠúŠwpW‰ïC‹à‘òC2017, 7.

E–Ø‘º‰p–¾C‚‹´O‹BC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“cºC‰““¡ŠiF’¼’°‘€ì‚É‚¨‚¯‚éA’¼Ž‹‰º‘€ì‚ɑ΂·‚éHALS‚Ì’·Š‚Æ’ZŠD‘æ8‰ñHALS Group MeetingC“Œ‹žC2017, 10.

E–Ø‘º‰p–¾C‚‹´O‹BC¼”ö‹§ŽjC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“cºC‰““¡ŠiF’×ᇫ‘å’°‰Š‚ÌpŒã’·ŠúŒo‰ß‚É‚¨‚¯‚釕¹Ç‚ÌŒŸ“¢D‘æ72‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïC•Ÿ‰ªC2017, 11.

E‚‹´O‹BF‰ŠÇ«’°Ž¾Š³‚É‚¨‚¯‚éÝ‘îŒoÖ¬‰h—{—Ö@‚ÌŒ»ó‚Æ–â‘è“_D‘æ24‰ñ_“ÞìIBDŒ¤‹†‰ïC‰¡•lC2017, 11.

E–Ø‘º‰p–¾Cˆäã‰p”üC¬” „C‘å’|‚Í‚é‚©C¼”ö‹§ŽjC‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“c ºC‰““¡ ŠiFƒNƒ[ƒ“•apŒãÄŽèp—á‚ÌŒ»ó‚Æ‘ÎôD‘æ25‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC•Ÿ‰ªC2017, 11.

E¬” „C¼”ö‹§ŽjC‘å’|‚Í‚é‚©C¼—Ñ^‰›C²X–Ø’q•FC’†ŒËì–ž’qŽqCˆäã‰p”üC–Ø‘º‰p–¾C‘è—æŽqF“–‰@‚ÅŒoŒ±‚µ‚½’n’†ŠC”M—Þ‰’°‰ŠiMEFV’°‰Šj‚Ì—Õ°“IE‰æ‘œ“I“Á’¥‚ÌŒŸ“¢D‘æ25‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC•Ÿ‰ªC2017, 11. iƒ|ƒXƒ^[—DG‰‰‘èÜj

E‘å’|‚Í‚é‚©C‹´–{ —IC¼”ö‹§ŽjC¬” „C¼—Ñ^‰›C²X–Ø’q•FC–Ø‘º‰p–¾C‘è—æŽqFIBDã•”Á‰»ŠÇ•a•Ï‚ɑ΂·‚éŒoŒû5-ƒAƒ~ƒmƒTƒŠƒ`ƒ‹Ž_»Ü•²Ó“Š—^‚Ì—L—p«D‘æ25‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC•Ÿ‰ªC2017, 11.

E‘å’|‚Í‚é‚©C‹´–{ —IC¼”ö‹§ŽjC¬” „C¼—Ñ^‰›C²X–Ø’q•FC–Ø‘º‰p–¾C‘è—æŽqCŠ}ˆäˆºŽqCÂ–Ø –ÎCŠÖ ˜a’jF“–‰@‚É‚¨‚¯‚éIBD‡•¹”DP‚ɑ΂·‚éRTNFƒ¿R‘̻ܓŠ—^‚̈À‘S«‚ÌŒŸ“¢D‘æ25‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC•Ÿ‰ªC2017, 11.

E¼”ö‹§ŽjCŽÅ“c ÂC‘å’|‚Í‚é‚©C¬” „Cã“c ÂC‘åì´FC•½àV‹ÓŒáC–Ø‘º‰p–¾C‘è—æŽqC–¡‰ª—mˆêC‘O“c œÄF’×ᇫ‘å’°‰Š‚É‚¨‚¯‚éserrated pathway‚ð‰î‚·‚éV‹KŽîᇔ­¶Œo˜H‚ÌŒŸ“¢D‘æ25‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC•Ÿ‰ªC2017, 11.

E‘å’|‚Í‚é‚©CΈä‹`lC‹à‘º’m‹PC‹´–{ —IC¼”ö‹§ŽjC¬” „C²X–Ø’q•FC–Ø‘º‰p–¾C‘è—æŽqFIBDã•”Á‰»ŠÇ•a•Ï‚ɑ΂·‚éŒoŒû5-ƒAƒ~ƒmƒTƒŠƒ`ƒ‹Ž_»Ü•²Ó“Š—^‚Ì—L—p«D‘æ8‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïiJSIBDjŠwpW‰ïC“Œ‹žC2017.11.

E‹´–{ —IC¬” „C‚‹´O‹BC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C²X–Ø’q•FC‘º“cˆËŽqC–Ø‘º‰p–¾C‘è—æŽqCŽR‘O³bFŠÖ߃ŠƒEƒ}ƒ`‚ɑ΂µ‚ăAƒoƒ^ƒZƒvƒg“Š—^’†‚É’×ᇫ‘å’°‰Š‚ð”­Ç‚µ‚½1—áD‘æ8‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïiJSIBDjŠwpW‰ïC“Œ‹žC2017.11.

E‚Ù‚©

(ŽóÜj

E¬” „i‘“à—¯Šw¶jFƒ|ƒXƒ^[—DG‰‰‘èÜD“–‰@‚ÅŒoŒ±‚µ‚½’n’†ŠC”M—Þ‰’°‰ŠiMEFV’°‰Šj‚Ì—Õ°“IE‰æ‘œ“I“Á’¥‚ÌŒŸ“¢D‘æ25‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC•Ÿ‰ªC2017, 11.

ã‚Ö–ß‚é

| 2016”N
(˜_•¶j

EKimura H, Kunisaki R, Tatsumi K, Koganei K, Sugita A, Endo I: Prolonged Medical Therapy Increases the Risk of Surgical Complications in Patients with Severe Ulcerative Colitis. Dig Surg, 33(3):182-189, 2016.

EKimura H, Takahashi K, Futami K, Ikeuchi H, Tatsumi K, Watanabe K, Maeda K, Watadani Y, Nezu R, Kameyama H, Nakao S, Kurachi K, Hotokezaka M, Otsuka K, Watanabe T, Ozawa H: Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan. Surg Today, 46(8):930-938, 2016.

EFeagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI-IM-UNITI Study Group: Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.N Engl J Med, 375(20):1946-1960, 2016.

EWatanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T: Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology, 151(6):1122-1130, 2016.

ETsuchiya K, Hayashi R, Fukushima K, Hibiya S, Horita N, Negi M, Itoh E, Akashi T, Eishi Y, Motoya S, Takeuchi Y, Kunisaki R, Fukunaga K, Nakamura S, Yoshimura N, Takazoe M, Iizuka B, Suzuki Y, Nagahori M, Watanabe M: CDX2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis. J Gastroenterol Hepatol, DOI: 10.1111/jgh.13645, 2016.

EKomoto S, Motoya S, Nishiwaki Y, Matsui T, Kunisaki R, Matsuoka K, Yoshimura N, Kagaya T,@Naganuma M, Hida N, Watanabe M, Hibi T, Suzuki Y, Miura S, Hokari R: Japanese study group for pregnant women with IBD; Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan. Intest Res, 14(2):139-45, 2016.

EKawakami A, Tanaka M, Ochiai R, Naganuma M, Kunisaki R, Kazuma K: Difficulties in Performing Mesalazine Enemas and Factors Related to Discontinuation Among Patients With Ulcerative Colitis. Gastroenterol Nurs, DOI: 10.1097/SGA.0000000000000147, 2016.

EHigashi D, Katsuno H, Kimura H, Takahashi K, Ikeuchi H, Kono T, Nezu R, Hatakeyama K, Kameyama H, Sasaki I, Fukushima K, Watanabe K, Kusunoki M, Araki T, Maeda K, Kameoka S, Itabashi M, Nakao S, Maeda K, Ohge H, Watadani Y, Watanabe T, Sunami E, Hotokezaka M, Sugita A, Funayama Y, Futami K: Current State of and Problems Related to Cancer of the Intestinal Tract Associated with Crohn's Disease in Japan. Anticancer Res, 36(7):3761-3766, 2016.

E“ñ–Ø —¹, ™“c º, ¬‹àˆäˆê—², ’C–¤Œ’Žu, •–Ø”Ž‰î, ŽR“c‹±Žq, rˆäŸ•F, –Ø‘º‰p–¾, •Ÿ“‡ P’jF‚—îŽÒ’×ᇫ‘å’°‰Š‚ɑ΂·‚é‰ñ’°”Xãè–åŠÇ•«‡p‚ÌpŒã”r•Ö‹@”\‚ÌŒŸ“¢. “ú–{Á‰»ŠíŠO‰ÈŠw‰ïŽGŽ, 49(8):714-720, 2016.

E‘DŽR—Œb, ¬–¸ç¹, ´…D, ‘è—æŽq, “¡Œ´•’j, ‰z’q^“Þ”ü, ‚‹´”üœ¨Žq, ¼‰ª•üŽq, ´…‘׊x, VˆäŸ‘åF¬Ž™ƒNƒ[ƒ“•aŠ³ŽÒ‚É‚¨‚¯‚é‰h—{—Ö@‚¨‚æ‚ÑHŽ–—Ö@‚ÌQOL‚Æ‚ÌŠÖ˜A«‚ɂ‚¢‚ÄD“ú–{Ö¬Œo’°‰h—{Šw‰ïŽGŽ, 31(2):718-724, 2016.

(Šw‰ï”­•\j

EOgashiwa T, Murakami M, Nishio M, Tsuda S, Kogure Y, Kasahara K, Hirai K, Fukuno Y, Jin M, Hanzawa A, Yonezawa H, Numata K, Kimura H, Kunisaki R: Transabdominal ultrasonography to assess intestinal wall thickness and vascularity appears to predict early response to steroids in moderate to severe ulcerative colitis. The 11th Congress of European Crohn's and Colotis Organization (ECCO) 2016, Amsterdam, 2016, 3.

EMurakami M, Kanemura T, Haga A, Kubota R, Yaguchi K, Nishio M, Tsuda S, Ogashiwa T , Kogure Y, Kasahara K, Hirai K, Fukuno Y, Jin M, Hanzawa A, Yonezawa H, Sakamaki K, Numata K, Kimura H, Kunisaki R: Usefulness of ultrasonography in the assessment of postoperative recurrence of Crohn's disease. The 9th Congress of European Crohn's and Colotis Organization (ECCO) 2016, Amsterdam, 2016, 3.

EKimura H, Kunisaki R, Tatsumi K, Koganei K, Sugita A, Endo I: One stage restorative proctocolectomy with a stapled ileal pouch-anal anastomosis using hand-assisted laparoscopic surgery (HALS) for ulcerative colitis. The American Society of Colon and Rectal Surgeons Annual Scientific Meeting, Los Angeles, 2016, 5.

ETsuda S, Kunisaki R, Kato J, Ogashiwa T, Nishio M, Murakami M, Kimura H: Are patient symptoms reliable enough to estimate endoscopic activity in ulcerative colitis patients?. Digestive Disease Week (DDW) 2016, San Diego, 2016, 5.

EOgashiwa T, Murakami M, Nishio M, Otake H, Matsubayashi M, Sasaki T, Nakatogawa M, Inoue E, Aoki S, Seki K, Kimura H, Kunisaki R: Pregnancy, delivery, and lactation in intestinal Behcet's disease patients. The 4th Annual Meeting of Asian Organization for Crohn's and Colitis (AOCC) 2016, Kyoto, 2016, 7.

EOtake H, Nishio M, Ogashiwa T, Matsubayashi M, Sasaki T, Nakatogawa M, Inoue E, Aoki S, Seki K, Kimura H, Kunisaki R: The safety of anti-TNFƒ¿ antibody treatment for inflammatory bowel disease during pregnancy in Japanese women The 4th Annual Meeting of Asian Organization for Crohn's and Colitis (AOCC) 2016, Kyoto, 2016, 7.

ENishio M, Yasuhara H, Otake H, Ogashiwa T, Matsubayashi M, Sasaki T, Nakatogawa M, Inoue E, Kimura H, Kunisaki R: Upper gastrointestinal lesions in Beh?et's disease. The 4th Annual Meeting of Asian Organization for Crohn's and Colitis (AOCC) 2016, Kyoto, 2016, 7.

E¬” „C‘ºã–ƒ—FC¼”ö‹§ŽjC’Óc‘–ëC’†ŒËì–ž’qŽqCŠ}Œ´N•½C¬•é—IC–Ø‘º‰p–¾C‘è—æŽqFŒo’°‰h—{—Ö@‚É‚æ‚èL”Í•a•Ï‚̉ü‘P‚ª“¾‚ç‚ê’·ŠúŠ°‰ð‚ðˆÛŽ‚µ‚Ä‚¢‚鬎™CDÇ—á@¬Ž™‚Ƭl‚ł͉h—{—Ö@‚Ö‚Ì”½‰ž«‚͈قȂé‚Ì‚©?D ‘æ16‰ñ“ú–{¬Ž™IBDŒ¤‹†‰ïC“Œ‹žC2016, 2.

E’Óc‘–ëC‘è—æŽqC‰Á“¡ ‡F’×ᇫ‘å’°‰Š‚É‚¨‚¯‚éVisual Analog Scale(VAS)‚É‚æ‚鎩ŠoÇó‚Ì•]‰¿‚Æ“àŽ‹‹¾“IŠˆ“®«‚Æ‚ÌŠÖ˜Aiƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“jD‘æ103‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ïC“Œ‹žC2016, 4.

E¬” „C‘è—æŽqCΈä‹`lC‘ºã–ƒ—FC¼”ö‹§ŽjC’Óc‘–ëC’†ŒËì–ž’qŽqC¬•é —IC–îàVŒcˆêCŒã“¡W‹IC–Ø‘º‰p–¾F‘å—ÊoŒŒ‚𔺂¤‚“xdǃXƒeƒƒCƒh’ïR«UC‚ɑ΂·‚éƒVƒNƒƒXƒ|ƒŠƒ“Ž‘±Ã’—Ö@‚Ì’ZŠúE’·ŠúŽ¡—ìÑD‘æ102‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ïC“Œ‹žC2016, 4.

E¼”ö‹§ŽjC‘è—æŽqC‘ºã–ƒ—FC’Óc‘–ëC¬” „C²X–Ø’q•FC’†ŒËì–ž’qŽqC¬•é —IC–Ø‘º‰p–¾C‘O“c œÄF“–‰@‚É‚¨‚¯‚鑽ܒïRE•s‘ϓ’×ᇫ‘å’°‰Š‚ɑ΂·‚éƒAƒ_ƒŠƒ€ƒ}ƒu‚ÌŽ¡—ìÑD‘æ103‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ïC“Œ‹žC2016, 4.

E‘ºã–ƒ—FC‘è—æŽqC–Ø‘º‰p–¾C¼“c—æŒ\C‹à‘º’m‹PC–F‰ê ‹ÅCÀ“c˜aŽiC⊪Œ°‘¾˜YFƒNƒ[ƒ“•apŒã•«‡•”Ä”­f’f‚É‚¨‚¯‚é‘ÌŠOŽ®’´‰¹”gŒŸ¸‚Ì—L—p«D‘æ103‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ïC“Œ‹žC2016, 4.

E–Ø‘º‰p–¾, ¬•é —I, ‘è—æŽq, ’C–¤Œ’Žu, ¬‹àˆäˆê—², ™“c º, ‰““¡ ŠiF“–‰@‚É‚¨‚¯‚é’×ᇫ‘å’°‰ŠpŒã”DPoŽY—á‚Ì“Á’¥D‘æ116‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïC‘åãC2016, 4.

E‘å’|‚Í‚é‚©C‘è—æŽqC¼”ö‹§ŽjC¬” „Cˆäã‰p”üC–Ø‘º‰p–¾F’Pƒ«’×ᇂ©‚ç•s‘SŒ^Beh?et•a‚Éi“W‚µCRTNFƒ¿R‘̻܂ÌswitchŒã‚ÉŒŒð«Ã–¬‰Š‚ªoŒ»‚µ‚½ˆê—áD‘æ33‰ñIBD•ƒx[ƒ`ƒFƒbƒg•aiB•BjŒ¤‹†‰ïC“Œ‹žC2016, 6.

E¬”@„C‹S“‡Ø“EC¼”ö‹§ŽjC‘å’|‚Í‚é‚©Cˆäã‰p”üC–Ø‘º‰p–¾C‘è—æŽqF‘½Ê‚È“àŽ‹‹¾ŠŒ©‚ð’æ‚·‚錴ˆö•s–¾’°‰Š‚Ì1—áD‘æ45‰ñ_“ÞìIBDƒ~ƒjƒJƒ“ƒtƒ@C‰¡•lC2016, 6.

E‘è—æŽqC‹S“‡Ø“EC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C¬” „Cˆäã‰p”üC–Ø‘º‰p–¾Ff’f‚É“ïa‚µ‚Ä‚¢‚é‰ñ–Ó•”Žîᇂ̈ê—áD‘æ45‰ñ_“ÞìIBDƒ~ƒjƒJƒ“ƒtƒ@C‰¡•lC2016, 6.

E¼”ö‹§ŽjC‘è—æŽqC‘å’|‚Í‚é‚©C¬” „Cˆäã‰p”üC–Ø‘º‰p–¾C‘O“c œÄF“–‰@‚É‚¨‚¯‚鑽ܒïRE•s‘ϓ’×ᇫ‘å’°‰Š‚ɑ΂·‚éƒAƒ_ƒŠƒ€ƒ}ƒu‚ÌŽ¡—ìÑD_“ÞìIBDƒtƒH[ƒ‰ƒ€C‰¡•lC2016, 6.

E–Ø‘º‰p–¾CŠ}Œ´N•½C‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“cºC‰““¡ŠiF¶•¨Šw“I»ÜŽž‘ã‚É‚¨‚¯‚éƒNƒ[ƒ“•apŒãÄŽèp—á‚ÌÄ”RŒ`Ž®‚Æ–â‘è“_D‘æ71‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ïC“¿“‡C2016, 7.

E¼”ö‹§ŽjC‘è—æŽqC‘O“cœÄFƒNƒ[ƒ“•a‚ɑ΂·‚éƒCƒ“ƒtƒŠƒLƒVƒ}ƒu”{—Ê“Š—^‚Ì’†Šú—\Œã‚Æ“KØ‚ÈŒø‰Ê”»’莞Šú‚ÌŒŸ“¢D‘æ24‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjiƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“jC_ŒËC2016, 11.

E¬” „C’JŒûŸéCÀ“c˜aŽiC¼”ö‹§ŽjC‘å’|‚Í‚é‚©C–Ø‘º‰p–¾C‘è—æŽqC‘O“c œÄFƒNƒ[ƒ“•a‚É‚¨‚¯‚é“÷Šá“IŠŒ©‚Æ…Z–@’´‰¹”gŒŸ¸‚É‚æ‚é•ÇŒú‚Ì‘ŠŠÖ‚ÉŠÖ‚·‚錟“¢D‘æ24‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjC_ŒËC2016, 11.

E–Ø‘º‰p–¾Aˆäã‰p”üA¼”ö‹§ŽjA’C–¤Œ’ŽuA¬‹àˆäˆê—²A™“cºA‰““¡ŠiFdÇ’×ᇫ‘å’°‰ŠŽ¡—Âɂ¨‚¯‚é“à‰È‚ÆŠO‰È‚̘AŒgD‘æ71‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïCŽOdC2016, 11.

E‚Ù‚©

(ŽóÜj

EΈä‹`liˆãŠw•”Šw¶jFPoster AwardD–Ɖu—}§Ž¡—Ã’†‚ɃTƒCƒgƒƒKƒƒEƒCƒ‹ƒX(CMV)Š´õ‚𕹔­‚µ‚½ƒNƒ[ƒ“•a‚Ì2Ç—áD‘æ7‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïiJSIBDjŠwpW‰ïC‹ž“sC2016.7.

E’JŒûŸéiˆãŠw•”Šw¶jFPoster AwardD‘S‚Ä‚ÌŠù‘¶Ž¡—ÂɒïR«‚ÅCƒVƒƒŠƒ€ƒX‚¨‚æ‚уNƒ‹ƒNƒ~ƒ“‚ª‘tŒ÷‚µ‚½“IBD‚Ì1—áD‘æ7‰ñ“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïiJSIBDjŠwpW‰ïC‹ž“sC2016.7.

E¬”@„i‘“à—¯Šw¶jFTravel Award of JSIBD for the 4th Annual Meeting of Asian Organization for Crohnfs and Colitis (AOCC). Pregnancy, delivery, and lactation in intestinal Behcetfs disease patientsC“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïC2016.

E¼”ö ‹§Žji‘åŠw‰@¶jFTravel Award of JSIBD for the 10th Congress of European Crohnfs and Colotis Organization (ECCO) . A novel candidate pathway for development of neoplasms with serrated morphology in patients with ulcerative colitisC“ú–{‰ŠÇ«’°Ž¾Š³Šw‰ïC2016.

ã‚Ö–ß‚é

| 2015”N
(˜_•¶j

EKimura H, Takahashi K, Futami K, Ikeuchi H, Tatsumi K, Watanabe K, Maeda K, Watadani Y, Nezu R, Kameyama H, Nakao S, Kurachi K, Hotokezaka M, Otsuka K, Watanabe T, Ozawa H: Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan. Surg Today, DOI 10.1007/s00595-015-1259-3, 2015.

ENumata A, Itabashi M, Kishimoto K, Motohashi K, Hagihara M, Kuwabara H, Tanaka M, Kato H, Chiba S, Kunisaki R, Fujisawa S: Intestinal amoebiasis in a patient with acute graft-versus-host disease after allogeneic bone marrow transplantation successfully treated by metronidazole. Transpl Infect Dis, 17:886-889, 2015.

EYoshimura N, Yokoyama Y, Matsuoka K, Takahashi H, Iwakiri R, Yamamoto T, Nakagawa T, Fukuchi T, Motoya S Kunisaki R, Kato S, Hirai F, Ishiguro Y, Tanida S, Hiraoka S, Mitsuyama K, Ishihara S, Tanaka S, Otaka M, Osada T, Kagaya T, Suzuki Y, Nakase H, Hanai H, Watanabe K, Kashiwagi N, Hibi T: An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. BMC Gastroenterol. 15:163, 2015.

EKawa S, Okazaki K, Notohara K, Watanabe M, Shimosegawa T; Study Group for Pancreatitis Complicated with Inflammatory Bowel Disease organized by The Research Committee for Intractable Pancreatic Disease (Chairman: Tooru Shimosegawa) and The Research Committee for Intractable Inflammatory Bowel Disease (Chairman: Mamoru Watanabe), both of which are supported by the Ministry of Health, Labour, and Welfare of Japan: Autoimmune pancreatitis complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis. J Gastroenterol, 50:805-815, 2015.

(Šw‰ï”­•\j

EKawakami A, Tanaka M, Yamamoto-Mitani N, Yoshimura N, Suzuki R, Maeda S, Kunisaki R : Application of a Japanese Version of the Morisky Medication Adherence Scale and Related Factors to Low Medication Adherence in Patient with Ulcerative Colitis. The 8th Congress of European Crohn's and Colotis Organization (ECCO) 2015, Valcerona, 2015, 2. (Oral Presentation).

EYasuhara H, Kunisaki R, Tsunoda S, Kawashima N, Yamamoto S, Tsuda S, Ogashiwa T, Koh R, Goto K, Kimura H, Numata K, Maeda S: Early transabdominal ultrasonography to assess intestinal wall thickness and vascularity appears to predict long-term outcome in Crhon's disease patients undergoing infliximab therapy:A prospective study. The 8th Congress of European Crohn's and Colotis Organization (ECCO) 2015, Valcerona, 2015, 2. (Poster Oral Presentation).

EOgashiwa T, Kunisaki R, Yasuhara H, Tsuda S, Koh R, Yazawa K, Gotoh K, Kimura H, Sugita A, Mori M, Tanaka M, Kanegane H, Maeda S: ClinicalCMorphological and Histological Features of X-linked Lymphoproliferative Syndrome Type 2 Enteritis Diagnosed in three Cases with Childhood Onset Inflammatory Bowel Disease. The 8th Congress of European Crohn's and Colotis Organization (ECCO) 2015, Valcerona, 2015, 2.

ETsuda S, Kunisaki R, Ogashiwa T, Yasuhara H, Koh R, Tsunoda S, Yamamoto S, Kawashima N, Kubota R, Yazawa K, Goto K, Kimura H, Maeda S. Efficacy and Nephrotoxicity of Long-term Maintenance Therapy with Tacrolimus in Patients with Ulcerative Colitis. The 8th Congress of European Crohn's and Colotis Organization (ECCO) 2015, Valcerona, 2015, 2.

EKimura H, Kuisaki R, Tatsumi K, Koganei K, Sugita A, Endo I : The effectiveness of biological therapy in the prevention of reoperation in patients with luminal Crohn disease. The American Society of Colon and Rectal Surgeons Annual Scientific Meeting, Boston, 2015, 5.

EFunayama R, Ogura C, Shimizu K, Kunisaki R, Takahashi M, Shimizu H, Arai K: Effect of Elemental Diet and Dietary Restriction on QOL in Children with Crohn's Disease. 12th Asian Congress of Nutrition, Yokohama, 2015, 5.

EDong Il Park, Young-Ho Kim, Suk-Kyun Yang, Byung-Ik Jang, Jae Hee Cheon, Geun Am Song, Jong Pil Im, Saruta M, Hibi TCWatanabe M, Kanai T, Katsuno T, Ishiguro Y, Kunisaki R, Kudo T, You-Kyung Kim, Nagaoka M, Isogawa N, Fabio Cataldi, Anindita Banerjee, Alaa Ahmad, Mina Hassan-Zahraee: Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA study in Asian population. The 3rd Annual Meeting of Asian Organization for Crohn's and Colotis (AOCC) 2015, Beijing, 2015, 6.

ESaruta M, Hibi T, Watanabe M, Kanai T, Katsuno T, Ishiguro Y, Kunisaki R, Kudo T, Dong Il PARK, Young-Ho KIM, Suk-Kyun YANG, Byung-Ik JANG, Jae Hee CHEON, Geun Am SONG, Jong Pil IM, Nagaoka M, Miyoshi S, Yinhua LI, Alaa AHMAD, Anindita BANERJEE, Fabio CATALDI: Pharmacokinetics of Anti-MAdCAM-1 Antibody (PF-00547659) in Crohn's Disease (CD) subjects in the OPERA Study: Comparison between Asian and Non-Asian populations. The 3rd Annual Meeting of Asian Organization for Crohn's and Colotis (AOCC) 2015, Beijing, 2015, 6.

EKimura H, Goto K, Kunisaki R, Tatsumi K, Koganei K, Sugita A, Inoue E, Endo I : Surgical timing for severe ulcerative colitis. The 70th General Meeting of JSGS, Hamamatsu, 2015, 7.

E¬” „C‘è—æŽqC–Ø‘º‰p–¾FNarrow Brand Imaging(NBI)Šg‘åŠÏŽ@‚Í’°ŠÇ‹}«GVHD‚Ì“àŽ‹‹¾f’f”\‚ð—LˆÓ‚ÉŒüコ‚¹‚éD‘æ89‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ïiƒ[ƒNƒVƒ‡ƒbƒvjC–¼ŒÃ‰®C2015, 5.

E’Óc‘–ëC‘è—æŽqC–Ø‘º‰p–¾FIBD‚ÌH“¹•a•Ï‚ÌŒŸ“¢D‘æ89‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ïiƒ[ƒNƒVƒ‡ƒbƒvjC–¼ŒÃ‰®C2015, 5.

E–Ø‘º‰p–¾C’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“cºCˆäã‰p”üC‰““¡@ŠiF“à‰ÈŽ¡—ÃŒø‰Ê•s\•ª‚ÈdÇ’×ᇫ‘å’°‰Š‚ɑ΂·‚鎊“KŽèpƒ^ƒCƒ~ƒ“ƒOD‘æ70‰ñ“ú–{‘å’°ãè–å•aŠw‰ïiƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“jC–¼ŒÃ‰®C2015, 11.

E–Ø‘º‰p–¾C¬•é—IC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“cºC‰““¡@ŠiFƒNƒ[ƒ“•apŒãÄŽèp—á‚ÌÄ”RŒ`Ž®‚ÆÄŽèp—\–h‚Ì‚½‚ß‚ÌŽ¡—ÕûjD‘æ77‰ñ“ú–{—Õ°ŠO‰ÈŠw‰ï‘‰ïiƒ[ƒNƒVƒ‡ƒbƒvjC•Ÿ‰ªC2015, 11.

E¬”@„C‘è—æŽqC‘ºã–ƒ—FC¼”ö‹§ŽjC’Óc‘–ëC¬•é —IC–Ø‘º‰p–¾C•½ˆäDC•Ÿ–ì‚悵‚ÝC_@”ü‹½C”¼àVH”¿C•ÄàVL”üC–F‰ê@‹ÅC‹à‘º’m‹PCΈä‹`lCŒE“c—¬•xlC’JŒûŸéCŠp“cãÄ‘¾˜YCÀ“c@˜aŽiF‘ÌŠOŽ®’´‰¹”gŒŸ¸‚É‚æ‚銈“®Šú’×ᇫ‘å’°‰Š‚ÌŽ¡—ÃŒø‰Ê—\‘ª‚ÌŒŸ“¢D‘æ33‰ñ“ú–{‘å’°ŒŸ¸Šw‰ï‘‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC“Œ‹žC2015, 11.

E–Ø‘º‰p–¾C¬•é—IC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“cºC‰““¡@ŠiF’×ᇫ‘å’°‰Š‚ɑ΂·‚é1Šú“I• o‹¾•â•‰ºiHALSj‘å’°‘S“EC‰ñ’°”Xãè–åŠÇ•«‡pD‘æ28‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ïiƒ[ƒNƒVƒ‡ƒbƒvjC‘åãC2015, 12.

E‚Ù‚©

ã‚Ö–ß‚é

| 2014”N
(˜_•¶j

ESasaki T, Kunisaki R, Kinoshita H, Yamamoto H, Kimura H, Hanzawa A, Shibata N, Yonezawa H, Miyajima E, Sakamaki K, Numata K, Tanaka K, Maeda S: Use of color Doppler ultrasonography for evaluating vascularity of small intestinal lesions in Crohn's disease: correlation with endoscopic and surgical macroscopic findings. Scand J Gastroenterol, 49:295-301, 2014.

ESasaki T, Kunisaki R, Kinoshita H, Kimura H, Kodera T, Nozawa A, Hanzawa A, Shibata N, Yonezawa H, Miyajima E, Morita S, Fujii S, Numata K, Tanaka K, Tanaka M, Maeda S: Doppler ultrasound findings correlate with tissue vascularity and inflammation in surgical pathology specimens from patients with small intestinal Crohn's disease. BMC Res Notes. 7:363, 2014.

EKawakami A, Tanaka M, Nishigaki M, Yoshimura N, Suzuki R, Maeda S, Kunisaki R, Yamamoto-Mitani N: A screening instrument to identify ulcerative colitis patients with the high possibility of current non-adherence to aminosalicylate medication based on the Health Belief Model: a cross-sectional study. BMC Gastroenterol, 14:220, 2014.

EHisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, Hirai F, Nagahori M, Matsushita M, Kobayashi K, Kishimoto M, Takeno M, Tanaka M, Inoue N, Hibi TFThe 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease : indication of anti-TNFƒ¿ monoclonal antibodies. J Gastroenterol, 49:156-62, 2014.

EFukata N, Okazaki K, Omiya M, Matsushita M, Watanabe M: Members of the Ministry of Health and Welfare of Japan's Inflammatory Bowel Diseases Study Group. J Gastroenterol, 49:1299-1306, 2014.

(Šw‰ï”­•\j

EKawakami A, Tanaka M, Nishigaki M, Yamamoto-Mitani N, Yoshimura N, Suzuki R, Maeda S, Kunisaki R: Development of an assessment method based on Health Belief Model to identify patient with ulcerative colitis at high-risk of non-adherence to aminosalicylates. The 9th Congress of European Crohn's and Colotis Organization (ECCO) 2014, Copenhagen, 2014, 2. (Oral Presentation).

EInagaki N, Kunisaki R, Sasaki T, Koh R, Kimura H, Wu R, Yaguchi K, Iizuka Y, Kobayashi K, Yagi S, Ookawara A, Miyajima E, Ohba M, Ohge H, Maeda S: Epidemiology and clinical features of bloodstream infections in patients with inflammatory bowel disease. The 9th Congress of European Crohn's and Colotis Organization (ECCO) 2014, Copenhagen, 2014, 2.

EKimura H, Kunisaki R, Tatsumi K, Koganei K, Sugita A, Endo I: Long periods of medical therapy increase surgical complications in patients with severe ulcerative colitis. The American Society of Colon and Rectal Surgeons annual scientific meeting, Florida, 2014, 5.

EOgata H, Yamamoto T, Kunisaki R, Ishida K, Hibi T: Efficacy, safety, and demographics factor of oral tacrolimus therapy in 666 Japanese patients with refractory ulcerative colitis. United European Gastroenterology (UEG) WeekVienna 2014, Vienna, 2014,9.

EArai K, Murakoshi T, Kakuta F, Kunisaki R, Kagimoto S, Ishige T, Mochizuki T, Inoue M, Iwama I, Shimizu T, Aomatsu T, Tajiri H, Iwata N, Nakayama Y, Shimizu H: JAPAN PEDIATRIC INFLAMMATORY BOWEL DISEASE REGISTRY -JUST EMBARKED. International Symposium on Pediatric Inflammatory Bowel Disease, Rotterdam, 2014, 9.

EˆîŠ_®ŽqC´…DC¼‰ª•üŽqCŽç‰®@—²C‹“‡‘å‰îC¬–¸ç¹CŽR–{šæŒbC–Ø‘º‰p–¾C‘è—æŽqC‘O“c@œÄF‰h—{—Ö@‚ɑ΂·‚éƒNƒ[ƒ“•aŠ³ŽÒ/‰Æ‘°‚̈ӎ¯‚Æ–â‘è“_`Ž©ìƒAƒ“ƒP[ƒg’²¸‚©‚ç`D‘æ29‰ñ“ú–{Ö¬Œo’°‰h—{Šw‰ïŠwpW‰ïiƒ[ƒNƒVƒ‡ƒbƒvjC‰¡•lC2014,2.

E´…DC¼‰ª•üŽqCŽç‰®@—²C‘è—æŽqCŽR–{šæŒbC¬–¸ç¹CˆîŠ_®ŽqC–Ø‘º‰p–¾FƒNƒ[ƒ“•aŠ³ŽÒ‚ÌHŽ–‚Ì’²—’S“–ŽÒiì‚èŽèj‚É‚¨‚¯‚éˆÓŽ¯‚Æ–â‘è“_‚ÌŒŸ“¢`ƒAƒ“ƒP[ƒg’²¸‚©‚ç`D‘æ29‰ñ“ú–{Ö¬Œo’°‰h—{Šw‰ïŠwpW‰ïiƒ[ƒNƒVƒ‡ƒbƒvjC‰¡•lC2014,2.

EˆîŠ_®ŽqCŽÅ“c@ÂC–Ø‘º‰p–¾C‘è—æŽqC²X–Ø’q•FC‚@˜@_C‘å’ë^—œC‘å–ÑGŠìC‘O“c@œÄF‰ŠÇ«’°Ž¾Š³Ç—á‚É‚¨‚¯‚éCVCŠÖ˜AŠ´õÇiCRBSIj‚̉uŠwC‹Nˆö‹Û‚¨‚æ‚ъ댯ˆöŽq‚̉ðÍ`’PŽ{Ý305—á‚ÌŒã•ûŽ‹ƒRƒz[ƒgŒ¤‹†‚©‚ç`D‘æ29‰ñ“ú–{Ö¬Œo’°‰h—{Šw‰ïŠwpW‰ïi—v–]‰‰‘èjC‰¡•lC2014,2.

E‘DŽR—ŒbC¬–¸ç¹C´…DC‘è—æŽqC‚‹´”üŒbŽqC‹ß“¡ƒŽqC¬ò(âˆä)—¢ŒbC´…NŠxCˆÉ“¡—æŽqCVˆäŸ‘åF¬Ž™ƒNƒ[ƒ“•aŠ³ŽÒ‚É‚¨‚¯‚é”­Ç‘OŒã‚Å‚ÌHKŠµ‚̕ω»‚ÆQOL‚Ö‚ÌŠÖ˜A«‚ɂ‚¢‚ÄD‘æ29‰ñ“ú–{Ö¬Œo’°‰h—{Šw‰ïŠwpW‰ïi—v–]‰‰‘èjC‰¡•lC2014,2.

E–Ø‘º‰p–¾C“c@ߊ°C‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“cºCˆäã‰p”üC‰““¡@ŠiF–ò•¨—Ö@‚Ìi•à‚ɉž‚¶‚½‰ŠÇ«’°Ž¾Š³‚ÌŠO‰ÈŽ¡—à ’×ᇫ‘å’°‰ŠŠO‰ÈŽ¡—Âɑ΂·‚éV‹K–ò•¨—Ö@‚̉e‹¿D‘æ114‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïiƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“jC‹ž“sC2014,4.

EˆîŠ_®ŽqC‘è—æŽqC‘O“c@œÄFƒ^ƒNƒƒŠƒ€ƒX“Š—^—ð‚©‚çŒŸ“¢‚µ‚½’×ᇫ‘å’°‰Š‚ɑ΂·‚éƒCƒ“ƒtƒŠƒLƒVƒ}ƒuŽ¡—Â̗L—p«D‘æ100‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ïiŽå‘艉‘èjC“Œ‹žC2014,4.

E²X–Ø’q•FC‘è—æŽqC–؉º—TlCŽR–{šæŒbC–Ø‘º‰p–¾CÀ“c˜aŽiC“c’†Ž–¾C‘O“c@œÄF“àŽ‹‹¾ŠŒ©‚¨‚æ‚ÑŽèp“÷ŠáŠŒ©‚Æ‚Ì”äŠr‚ÉŠî‚­ƒNƒ[ƒ“•a¬’°•a•Ï‚ɑ΂·‚éƒJƒ‰[ƒhƒvƒ‰’´‰¹”gŒŸ¸‚É‚æ‚錌—¬•]‰¿D‘æ87‰ñ“ú–{Á‰»Ší“àŽ‹‹¾Šw‰ï‘‰ïiƒvƒŒƒiƒŠ[ƒZƒbƒVƒ‡ƒ“jC•Ÿ‰ªC2014,5.

E–Ø‘º‰p–¾C‘è—æŽqC‰““¡ŠiFƒNƒ[ƒ“•a’°ŠÇŽèpŒã‚É‚¨‚¯‚鶕¨Šw“I»Ü‚ÌÄŽèp—\–hŒø‰ÊD‘æ22‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjiƒVƒ“ƒ|ƒWƒEƒ€jC_ŒËC2014,10.

E‘è—æŽqC–Ø‘º‰p–¾C‘O“c@œÄF“’×ᇫ‘å’°‰Š‚ɑ΂·‚éTacrolimus‚É‚æ‚é’·ŠúŽ¡—ìÑ@Žèp‰ñ”𗦂̌Ÿ“¢D‘æ22‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjiƒ[ƒNƒVƒ‡ƒbƒvjC_ŒËC2014,10.

E´…DC‘è—æŽqC‘DŽR—ŒbC‚‹´”üœ¨ŽqC¬–¸ç¹C´…‘׊xCVˆäŸ‘åC’Óc‘–ëCˆÀŒ´‚Ђ³ŒbC¬”@„C‚@˜@_C’†ŒËì–ž’qŽqC–îàVŒcˆêC–Ø‘º‰p–¾C¼‰ª•üŽqCŽç‰®@—²FƒNƒ[ƒ“•aŠ³ŽÒ‚É‚¨‚¯‚é”­•a‘OŒã‚ÌH¶Šˆ‚̕ω»‚ÆHŽ–“à—e‚É‚æ‚é‘Ì’²•Ï‰»‚ÌŒŸ“¢`ƒAƒ“ƒP[ƒg’²¸‚©‚ç`D‘æ11‰ñ“ú–{Ý‘îÖ¬Œo’°‰h—{Œ¤‹†‰ïŠwpW‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC“Œ‹žC2014,10.

E–Ø‘º‰p–¾C–îàVŒcˆêC‚˜@_C‘è—æŽqC’C–¤Œ’ŽuC¬‹àˆäˆê—²C™“c@ºCˆäã‰p”üC‰““¡@ŠiFIBD‚ÌŽèp Hand assisted laparoscopic surgery(HALS)‚ÆVideo assisted intrapelvic surgery(VIPS)‚É‚æ‚éˆêŠú“I‘å’°‘S“EC‰ñ’°”Xãè–åŠÇ•«‡pD‘æ69‰ñ‘å’°ãè–å•aŠw‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC‰¡•lC2014,10.

EˆÀŒ´‚Ђ³ŒbC‘è—æŽqC’Óc‘–ëC¬”@„C‚@˜@_C–îàVŒcˆêC–Ø‘º‰p–¾C‘O“c@œÄF“–‰È‚ÅŒoŒ±‚µ‚½ƒAƒ[ƒo«‘å’°‰Š‚ÌŒŸ“¢D‘æ69‰ñ‘å’°ãè–å•aŠw‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC‰¡•lC2014,10.

E‚Ù‚©

ã‚Ö–ß‚é

| 2013”N
(˜_•¶j

EKinoshita H, Kunisaki R, Yamamoto H, Matsuda R, Sasaki T, Kimura H, Tanaka K, Naganuma M, Maeda S. Efficacy of infliximab in patients with intestinal Behcet's disease refractory to conventional medication.@Intern Med,52:1855-62, 2013.

ENaganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease.@J Gastroenterol, 48:595-600, 2013.

ENaganuma M, Fujii T, Kunisaki R, Yoshimura N, Takazoe M, Takeuchi Y, Saito E, Nagahori M, Asakura K, Takebayashi T, Watanabe M. Incidence and characteristics of the 2009 influenza (H1N1) infections in inflammatory bowel disease patients. J Crohns Colitis, 7:308-13, 2013.

EKawakami A, Tanaka M, Nishigaki M, Naganuma M, Iwao Y, Hibi T, Sanada H, Yamamoto-Mitani N, Kazuma K. Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese with ulcerative colitis in clinical remission: A prospective cohort study. Journal of Gastroenterology, 48:1006-15, 2013.

(Šw‰ï”­•\j

EKinoshita H, Kunisaki R, Sasaki T, Kimura H, Tanaka K, Okuda M, Takahashi T, Hirawa S, Maeda S: Efficacy and Safety of Therapeutic Apheresis in Four Cases of Pregnant Women with Inflammatory Bowel Disease. 8th Congress of European Crohn's and Colotis Organization (ECCO) 2013, Vienna, 2013, 2.

EKinoshita H, Kunisaki R, Ikeda R, Matsubayashi M, Sasaki T, Kimura H, Tanaka K, Naganuma M, Maeda S: Short- and long-term efficacy of infliximab in intestinal Behcet's disease refractory to conventional medications indicates a major role for tumour necrosis factor-ƒ¿. The 8th Congress of European Crohn's and Colotis Organization (ECCO) 2013, Vienna, 2013, 2.

ETanaka M, Kawakami A, Iwao Y, Fukushima T, Nishigaki M, Suzuki M, Sanada H, Yamamoto-Mitani N: Coping strategies for worsening conditions and their perceived effectiveness in patients with inflammatory bowel disease. The 8th Congress of European Crohn's and Colotis Organization (ECCO) 2013, Vienna, 2013, 2.

ESasaki T, Kunisaki R, Kinoshita H, Kimura H, Kodera T, Nozawa A, Hanzawa A, Shibata N, Yonesawa H, Miyajima E, Morita S, Fujii S, Numata K, Tanaka K, Tanaka M, Maeda S: Doppler Ultrasound findings correlate with tissue vascularity and inflammation with surgical pathology in Small Intestinal Crohn's Disease LesionsFClinically Silent or Difficult to Reach by Endoscopy. Digestive Disease Week 2013. Orland, 2013, 5.

EKinoshita H, Kunisaki R, Sasaki T, Kimura H, Tanaka K, Maeda S: Clinical characteristics and colectomy rate in the patients with ulcerative colitis who are intolerance to 5-aminosalycylic acid agents: a single-center cohort study. Digestive Disease Week 2013. Orland, 2013, 5.

EShibata W, Kunisaki R, Sasaki T, Kinoshita H, Kimura H, Hanzawa A, Shibata N, Yonesawa H, Miyajima E, Numata K, Maeda S: CDUS (Color Doppler Ultrasound) is sensitive nonionizing technique to identify the affected small bowel segments and transmural complications, supporting to predict the treatment response in patients with active Crohn's disease. Digestive Disease Week 2013, Orland, 2013, 5.

EKinoshita H, Kunisaki R, Sohara M, Taniguchi K, Wu R, Nakahata H, Iwasa M, Yamaguchi T, Matsumoto H, Okada M, Inasawa M, Hayashi A, Sasaki T, Yamamoto H, Matsuda R, Inagaki N, Koh R, Kimura H, Maeda S: Clinical characteristics and colectomy rate in the patients with ulcerative colitis who are intolerance to 5-aminosalycylic acid agents : a single-center cohort study. The 1st annual meeting of Asian Organization for Crohn's • Colitis (AOCC), Tokyo, 2013, 6.

EKinoshita H, Kunisaki R, Sohara M, Taniguchi K, Wu R, Nakahata H, Iwasa M, Yamaguchi T, Matsumoto H, Okada M, Inasawa M, Hayashi A, Sasaki T, Yamamoto H, Matsuda R, Inagaki N, Koh R, Kimura H, and Maeda S: Descriptive data of clinical course and outcomes of adverse events of 5-aminosalycylic acid agents : a single-center cohort study. The 1st annual meeting of Asian Organization for Crohn's • Colitis (AOCC), Tokyo, 2013, 6.

EWu R, Sohara M, Shibata W, Kunisaki R, Iwasa M, Nakahata H, Yamaguchi T, Matsumoto H, Okada M, Taniguchi K, Hayashi A, Inasawa M, Iizuka Y, Kobayashi K, Yagi S, Yaguchi K, Inagaki N, Koh R, Sasaki T, Kimura H, Ookawara A, Miyajima E, Ohge H, Maeda S: Incidence and risk factors for blood stream infection in patients with inflammatory bowel disease. The 1st annual meeting of Asian Organization for Crohn's • Colitis (AOCC), Tokyo, 2013, 6.

E–Ø‘º‰p–¾CŒ´“c^ŒáCˆäã‰p”üC’r“c—Ç•ãC²X–Ø’q•FC–؉º—TlC‘è—æŽqC¬‹àˆäˆê—²C™“c ºC‰““¡ ŠiFƒNƒ[ƒ“•a’°ŠÇ•a•Ï‚ÌŠO‰ÈŽ¡—Âɂ¨‚¯‚éV‚½‚ÈŽ¡—Ãí—ªD‘æ68‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ï‘‰ïiƒ[ƒNƒVƒ‡ƒbƒvjC‹{èC2013,7.

E–Ø‘º‰p–¾, ‘è—æŽq, ‰““¡ ŠiFpŒã‡•¹Ç‚©‚ç‚Ý‚½dÇ’×ᇫ‘å’°‰Š‚É‚¨‚¯‚é“à‰È“IŽ¡—Â̌ÀŠED‘æ21‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiDDW-JAPANjiƒVƒ“ƒ|ƒWƒEƒ€jDVhC2013.10.

E‚Ù‚©

(ŽóÜj

ESasaki Ti‘åŠw‰@¶jFPoster of Distinction. Doppler Ultrasound findings correlate with tissue vascularity and inflammation with surgical pathology in Small Intestinal Crohnfs Disease LesionsFClinically Silent or Difficult to Reach by Endoscopy. Digestive Disease Week 2013.

ã‚Ö–ß‚é

| 2012”N
(˜_•¶j

ENaganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M: A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease.J Gastroenterol, 2012.

ENaganuma M, Fujii T, Kunisaki R, Yoshimura N, Takazoe M, Takeuchi Y, Saito E, Nagahori M, Asakura K, Takebayashi T, Watanabe M: Incidence and characteristics of the 2009 influenza (H1N1) infections in inflammatory bowel disease patients. J Crohns Colitis, 2012.

(Šw‰ï”­•\j

EOgura C, Arai KCToyoda S, Kunisaki R: Psychological Adaptation Process to Nutritional and Dietary Intervention in Adolescents with Inflammatory Bowel Disease. The 8 th Congress of Asian Society for Pediatric Research. Seoul, 2012,5.

EKinoshita H, Kunisaki R, Yamamoto H, Matsuda R, Nakatogawa M, Kimura H, Tanaka K, Maeda S: Efficacy and Safety of Infliximab in Intestinal Behcet's Disease. Digestive Disease Week (DDW) 2012, San Diego, 2012,5.

EŽR–{šæŒbC{‰ê‘×¢C–؉º—TlC¼“c—æŒ\C’†ŒËì–ž’qŽqC—é–Øa—TC–Ø‘º‰p–¾C‘è—æŽqC‘O“c œÄFŠˆ“®Šú’×ᇫ‘å’°‰Š‚ɑ΂·‚鬕ª‰h—{Ü“Š—^‚ÌŒŸ“¢D‘æ27‰ñ“ú–{Ö¬Œo’°‰h—{Šw‰ïiƒ~ƒjƒ[ƒNƒVƒ‡ƒbƒvjC_ŒËC2012,2.

E´…DC¼‰ª•üŽqCŽç‰®@—²C‘è—æŽqCŽR–{šæŒbC¬–¸ç¹C–Ø‘º‰p–¾C‹“‡‘å‰îC“c’†’qŽqC‹àŽq—FŽqC‘å’Ë«GCŽRì ³: ƒNƒ[ƒ“•a‚Ì”­•a‘OŒã‚É‚¨‚¯‚éHŽ–•Ï‘J‚ÆHŽ–—Ö@‚É‚¨‚¯‚é–â‘è“_`ƒAƒ“ƒP[ƒg’²¸‚©‚ç`D‘æ27‰ñ“ú–{Ö¬Œo’°‰h—{Šw‰ïiƒ~ƒjƒ[ƒNƒVƒ‡ƒbƒvjC_ŒËC2012,2.

E–Ø‘º ‰p–¾, —é–Ø a—S, ‘è —æŽq, ¬‹àˆä ˆê—², ™“c º, ‰““¡ Ši:‰ŠÇ«’°Ž¾Š³‚ɑ΂·‚éŠO‰ÈŽ¡—Â̌»‹µ‚Æ“W–] dÇ’×ᇫ‘å’°‰Š‚ɑ΂·‚éŠO‰ÈŽ¡—ÃD‘æ112‰ñ“ú–{ŠO‰ÈŠw‰ï’èŠúŠwpW‰ïiƒVƒ“ƒ|ƒWƒEƒ€j, ç—tC2012,4.

E²X–Ø’q•FC‘è—æŽqC–Ø‘º‰p–¾C_ ”ü‹½C”¼àVH”¿CŽÄ“c®”üC•ÄàVL”üC‹{“‡‰hŽ¡C“¡ˆä³ˆêCÀ“c˜aŽiC“c’†Ž–¾C¬Ž›‹P–¾C–ìàVº“TC“c’†³‘¥C‘O“c œÄ:ƒNƒ[ƒ“•a¬’°•a•Ï‚ÌŠˆ“®«f’f‚É‚¨‚¯‚é‘ÌŠOŽ®’´‰¹”gƒhƒvƒ‰–@‚Ì—L—p«‚ÉŠÖ‚·‚éŠî‘b“IŒŸ“¢D‘æ30‰ñ‘å’°ŒŸ¸Šw‰ï‘‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC“Œ‹žC2012,9.

EŽR–{šæŒbC{‰ê‘×¢C–؉º—TlC¼“c—æŒ\C¼—Ñ^‰›C’†ŒËì–ž’qŽqCˆäã‰p”üC–Ø‘º‰p–¾C‘è—æŽqC‘O“c œÄ:Á‰»‹zŽû‚Ì‘¤–Ê‚©‚ç‚Ý‚½‰ŠÇ«’°Ž¾Š³‚Ì•a‘ԂƉh—{—Ö@ dÇ’×ᇫ‘å’°‰Š‚ɑ΂·‚éŒo’°‰h—{Ü“Š—^‚Ì—L—p«D‘æ20‰ñ“ú–{Á‰»ŠíŠÖ˜AŠw‰ïTŠÔiJDDWjiƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“jC_ŒËC2012,10.

E–Ø‘º‰p–¾, ˆäã‰p”ü, ‘è—æŽq, ¬‹àˆäˆê—², ™“c º, ‰““¡ Ši: IBDf—Âɂ¨‚¯‚éŠO‰È‚Æ“à‰È‚ÌÚ“_(“Ǘá‚ÌŽ¡—Õûj) pŒã‡•¹Ç‚©‚ç‚Ý‚½dÇ’×ᇫ‘å’°‰Š‚ɑ΂·‚鎡—Ãí—ªD‘æ67‰ñ“ú–{‘å’°ãè–å•aŠw‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC•Ÿ‰ªC2012,11.

E¬–¸ç¹, ‘è—æŽq, ˆäã‰p”ü, ¼—Ñ^‰›, ²X–Ø’q•F, –؉º—Tl, –Ø‘º‰p–¾, ‘O“c œÄ, ‰““¡ Ši: ’×ᇫ‘å’°‰Š‚ÌpŒã¬Ñ‚ÆQOL•]‰¿ ’×ᇫ‘å’°‰ŠŽüpŠú‚É‚¨‚¯‚銳ŽÒ‚ÌS“I•Ï‘J‚ÆQOL‚ÌŒŸ“¢D‘æ67‰ñ“ú–{‘å’°ãè–å•aŠw‰ïiƒ[ƒNƒVƒ‡ƒbƒvjC•Ÿ‰ªC2012,11.

E‚Ù‚©

ã‚Ö–ß‚é

| 2011”N
(˜_•¶j

EKaneko T, Matsuda R, Taguri M, Inamori M, Ogura A, Miyajima E, Tanaka K, Maeda S, Kimura H, Kunisaki R: Clostridium difficile infection in patients with ulcerative colitis: investigations of risk factors and efficacy of antibiotics for steroid refractory patients. Clin Res Hepatol Gastroenterol, 35:315-20, 2011.

ENaganuma M, Kunisaki R, Yoshimura N, Nagahori M, Yamamoto H, Kimura H, Sako M, Kawaguchi T, Takazoe M, Yamamoto S, Matsui T, Hibi T, Watanabe M: Conception and pregnancy outcome in women with inflammatory bowel disease: A multicentre study from Japan. J Crohns Colitis, 5:317-23, 2011.

(Šw‰ï”­•\j

E¼“c—æŒ\, ŽR–{šæŒb, ‘è—æŽqF’°“à׋ۂƉŠÇ«’°Ž¾Š³ “–‰@‚Ì’×ᇫ‘å’°‰ŠŠ³ŽÒ‚É‚¨‚¯‚éClostridium difficileŠ´õ‚̇•¹•p“x‚Ɗ댯ˆöŽq‚ÌŒŸ“¢D‘æ97‰ñ“ú–{Á‰»Ší•aŠw‰ïiƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“jC“Œ‹žC2011C5.

E‘è—æŽq, ŽR–{šæŒb, ‘O“c@œÄF‰ŠÇ«’°Ž¾Š³Ž¡—Âł̶•¨Šw“I»Ü‚â–Ɖu’²®–ò‚Í‚±‚¤Žg‚¤! “«’×ᇫ‘å’°‰Š‚ɑ΂·‚éTacrolimus“Š—^–@‚Æ—LŒø«‚É—^‚¦‚éˆöŽq‚ÌŒŸ“¢D‘æ97‰ñ“ú–{Á‰»Ší•aŠw‰ïiƒ[ƒNƒVƒ‡ƒbƒvjC“Œ‹žC2011C5.

E–Ø‘º‰p–¾, ‚‹´’¼s, ã “Þ’ÃŽq,ŽR–{šæŒb, ‘è—æŽq,¬‹àˆäˆê—², ™“c º,‰““¡ ŠiF‰ŠÇ«’°Ž¾Š³‚ɑ΂·‚éŠO‰ÈŽ¡—ÂƬÑ@¶•¨Šw“I»Ü“±“üŒã‚É‚¨‚¯‚éƒNƒ[ƒ“•a‚ÌŠO‰ÈŽ¡—ìÑD‘æ66‰ñ“ú–{Á‰»ŠíŠO‰ÈŠw‰ïiƒ[ƒNƒVƒ‡ƒbƒvjC–¼ŒÃ‰®C2011C7.

EŽR–{šæŒbC‘è—æŽqC–؉º—TlC¼“c—æŒ\C—é–Øa—SC–Ø‘º‰p–¾C—é–Ø—ºˆêCš èŽåÅC‘O“c@œÄFƒNƒ[ƒ“•a‚ɑ΂·‚éInfliximab‚Ì—LŒø«‚ÉŠÖ‚í‚éˆöŽq‚ÌŒŸ“¢D’×ᇕa‘ÔŒ¤‹†‰ï@‘æ20‰ñƒtƒH[ƒ‰ƒ€iƒVƒ“ƒ|ƒWƒEƒ€jC“Œ‹žC2011,7.

E–؉º—TlC‘è—æŽqCŽR–{šæŒbC¼“c—æŒ\C’†ŒËì–ž’mŽqC—é–Øa—SC–Ø‘º‰p–¾C‘O“c œÄFƒ^ƒNƒƒŠƒ€ƒX‚É‚æ‚é’×ᇫ‘å’°‰ŠŽ¡—Âɂ¨‚¯‚é“àŽ‹‹¾ŒŸ¸‚Ì—L—p«D‘æ29‰ñ‘å’°ŒŸ¸Šw‰ï‘‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC“Œ‹žC2011.9.

E‚Ù‚©

ã‚Ö–ß‚é

| 2010”N
(˜_•¶j

EHarada T, Ito S, Sasaki T, Kunisaki R, Shiojima H, Ogawa M, Yokota S. GI involvement of sigmoid mucosal erosion in a 13-year-old girl with microscopic polyangiitis. Gastrointest Endosc, 2010.

(Šw‰ï”­•\j

EHisae Y, Kunisaki R, Nakatogawa M, Matsuda R, Minami Y, Kimura H, Yamaguchi M, Okuda M, Takahashi T. Pregnancy outcome in patients with ulcerative colitis. The 4th Korea-Japan IBD Symposium. Tokyo, 2010,1.

EChisa Shindo: Psychological aspects of nutritional and dietary interventions in adolescents with Crohn's disease. ‘æ37‰ñ“ú–{¬Ž™‰h—{Á‰»ŠíŠÌ‘Ÿ•aŠw‰ïiƒVƒ“ƒ|ƒWƒEƒ€j, ‚¼C2010,10.

E‘è—æŽqCŽR–{šæŒbC“ì —S‘¾C–Ø‘º‰p–¾CŽÄ“c®”üC•ÄàVL”üC”¼àVH”¿C‹{“‡‰hŽ¡C²X–Ø’q•FCÀ“c˜aŽiC²X–Ø ‹BC–ì‘òº“TF‘ÌŠOŽ®’´‰¹”gŒŸ¸‚É‚æ‚éƒNƒ[ƒ“•a¬’°•a•Ï‚Ì•]‰¿D‘æ8‰ñ‘å’°ƒAƒJƒfƒ~[iCIAjiƒVƒ“ƒ|ƒWƒEƒ€jC“Œ‹žC2010,1.

EŽR–{šæŒb, –Ø‘º‰p–¾, ‘è—æŽqD•a‘Ô‚©‚ç‚Ý‚½‰ŠÇ«’°Ž¾Š³‚ÌV‚µ‚¢Ž¡—ÑI‘ðF“–‰@‚É‚¨‚¯‚éTacrolimus‚É‚æ‚éInfliximab’ïR«ƒNƒ[ƒ“•a‚ɑ΂·‚鎡—ÃŒoŒ±DJDDW2010iƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“jC‰¡•lC2010,10.

E–Ø‘º‰p–¾, ‘è—æŽq, åM‰º‘×G, ŽR–{šæŒb, ã“Þ’ÃŽq, ¬‹àˆäˆê—², ™“cº, ‰““¡ŠiDIBD“EdÇ—á‚ÌŽ¡—Ãí—ª ŠO‰ÈŽ¡—ÂƃTƒCƒNƒƒXƒ|ƒŠƒ“—Ö@‚ÌŽ¡—ìт©‚ç‚Ý‚½dÇ’×ᇫ‘å’°‰Š‚ÌŽ¡—ÕûjD‘æ65‰ñ“ú–{‘å’°ãè–å•aŠw‰ïŠwpW‰ïiƒVƒ“ƒ|ƒWƒEƒ€j, •l¼C2010.11.

E‘è—æŽqCŽÄ“c®”üC”¼àVH”¿C•ÄàVL”üC‘哇—‰ÁC“¡àV MC–ì‘òº“TD¬’°ˆ««ƒŠƒ“ƒpŽî‚ɑ΂·‚é‘ÌŠOŽ®’´‰¹”gŒŸ¸‚Ì—L—p«D‘æ28‰ñ‘å’°ŒŸ¸Šw‰ï‘‰ïiƒVƒ“ƒ|ƒWƒEƒ€jC“Œ‹žC2010.11.

E‚Ù‚©

ã‚Ö–ß‚é